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ABSTRACT 
TAILORING THE SURFACE-COATING OF GOLD NANOPARTICLES FOR BIO-
APPLICATIONS 
 
SEPTEMBER 2009 
 
PARTHA S. GHOSH, B.Sc., RAMAKRISHNA MISSION VIDYAMANDIRA 
 
M.Sc., INDIAN INSTITUTE OF TECHNOLOGY KANPUR 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Vincent M. Rotello 
 
 
Functionalized gold nanoparticles (AuNPs) provide an excellent scaffold for 
numerous biological applications. In these systems, the gold core imparts stability to the 
assembly, while the monolayer allows tuning of surface characteristics such as charge 
and hydrophobicity. The nano-scale size and tunable surface properties have made them 
an ideal candidate for manipulating protein-protein/protein-nucleic acid interactions, and 
delivery of therapeutics. In this thesis work, it has been demonstrated how the surface 
coating plays an important role in achieving a desired goal. Using organic synthesis as a 
tool, the monolayer was tailored to afford useful particles with biocompatibility and the 
ability to respond in the cellular environment. The recognition units present on the 
periphery of particles dictates/controls their interactions with biomolecular or cell 
surfaces. As described here, these engineered particles exhibited a number of bio-
applications, including folding of a peptide into an α-helix, binding with DNA, and 
cellular delivery of genes and proteins.  
  viii 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Nanoparticles: An Excellent Scaffold for Biological Applications 
Nanobiotechnology has emerged as a new exciting field in recent years with much 
promise.1 The use of nanomaterials in biotechnology merges the fields of material 
science and biology. Nanoparticles offer a useful platform, providing unique properties 
with potentially wide-ranging therapeutic applications.2 The field of nanoparticles in 
biology is certainly a burgeoning one, with the estimated number of papers in the area 
(based on Web of Science) rising from 11 in 1991 to over 3400 in 2008. 
The utility of nanoparticles (NPs) arises from a variety of desirable structural 
attributes, including the similar size of nanoparticles and biomolecules such as proteins 
and polynucleic acids (Figure 1.1).3 Additionally, nanoparticles can be fashioned with a 
wide range of metal and semiconductor core materials that impart useful properties such 
as fluorescence and magnetic behavior.4 The applicable properties of some well known 
core materials and corresponding possible ligands used for surface functionalization with 
their possible applications are summarized in Table 1.1.  
 
Figure 1.1: Schematic representation of a 2 nm core gold nanoparticle with 11-
mercaptoundecanoic acids monolayer and relative sizes of papain and a 24-mer DNA 
duplex. 
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Nanoparticles are promising candidates for various biomedical applications, 
including biosensing, diagnostics, and therapy.5,6,7,8,9 My research was focused on the use 
of gold nanoparticles in cellular delivery. As a background to this work, two related areas 
have been discussed here, namely nanoparticle-biomolecule interactions and 
nanoparticles as drug delivery systems. 
Table 1.1: Characteristics, ligands and representative applications for various metal and 
semiconductor materials. 
 
Core material Characteristics  Ligand Applications 
Au Optical absorption, 
fluorescence and 
fluorescence 
quenching, stability 
Thiol, disulfide, 
phosphine, 
amine 
Biomolecular 
recognition, 
delivery, sensing 
Ag Surface-enhanced 
fluorescence 
Thiol Sensing 
Pt Catalytic property Thiol, 
phosphine, 
amine, 
isocyanide 
Bio-catalyst, 
sensing 
CdSe Luminescence, photo-
stability 
Thiol, 
phosphine, 
pyridine 
Imaging, sensing 
Fe2O3 Magnetic property Diol, dopamine 
derivative, 
amine 
MR imaging and 
biomolecule 
purification 
SiO2 Biocompatibility Alkoxysilane Biocompatible by 
surface coating  
 
1.2 Nanoparticle-Biomolecule Interactions 
Creation of nanoparticle-based artificial receptors for biomacromolecular surface 
recognition provides a potential tool for controlling cellular and extracellular processes in 
numerous biological applications such as transcription regulation, enzymatic inhibition, 
delivery and sensing.  
  3
The conjugation of nanoparticles with biomolecules, such as proteins and DNA, 
can be done using two different approaches: direct covalent linkage and non-covalent 
interactions.10,11,12,13,14 The most direct approach involves covalent attachment.15 This 
conjugation can be achieved through either chemisorption of the biomolecule to the 
particle surface or through the use of heterobifunctional linkers. Chemisorption of 
proteins onto the surface of nanoparticles (usually containing a core of Au, ZnS, CdS and 
CdSe/ZnS) can be done through cysteine residues that are present on the protein surface 
(e.g. oligopeptide, serum albumin),16 or chemically using 2-iminothiolane (Traut’s 
reagent).17,18 Bifunctional linkers provide a more versatile means of bioconjugation. 
Biomolecules are often covalently linked to ligands on the NP surface via traditional 
coupling strategies such as carbodiimide-mediated amidation and esterfication.19 For 
biological applications, OEG or PEG is used in the linker to enhance the stability of the 
attached biomolecules and minimize non-specific adsorption of other materials.  
Non-covalent assembly provides a highly modular approach to the 
biofunctionalization of nanoparticles.  One example is DNA-NP binding, which can be 
effected through electrostatic interactions, groove binding, intercalation and 
complementary single strand DNA binding.20 In this case, nanoparticles provide an 
attractive receptor for nucleic acids, representing a close analogy to protein-DNA 
interactions.21,22 One approach to particle-DNA assembly uses complementary 
electrostatic interactions to promote high affinity of nanoparticle-DNA binding. The use 
of cationic ligands on the nanoparticle surface provides a complementary surface for 
binding the negatively charged backbone of DNA, for example the use of NP 1 to bind to 
a 37-mer DNA duplex (Figure 1.2).23 The binding of DNA inhibited transcription by T7 
  4
RNA polymerase, indicating the high affinity of the NP-DNA complex and pointing out a 
potential use of these systems in gene regulation. Intercalation provides yet another 
mechanism for DNA binding, as demonstrated by Murray et al.24 A third approach to 
DNA conjugation exploits the high affinity and specificity of base-paring between DNA 
strands (Figure 1.2c).25  
 
 
Figure 1.2: The DNA-nanoparticle interactions. (a) Structure of NP 1 scaffold and the 
DNA backbone. (b) Transcription level as a function of DNA-NP 1 stoichiometry. (c) 
Binding of DNA through complementary oligonucleotide hybridization. 
 
Nanoparticle-protein interactions have also been studied extensively. One system 
that has been explored in our lab is the binding of chymotrypsin (ChT) - targeting the ring 
of cationic residues around active site of ChT (Figure 1.3).26 Time-dependent inhibition 
of ChT activity was observed upon incubation with negatively charged NP 2.27 A two-
step binding process with a fast reversible association followed by a slower irreversible 
denaturation was observed.28 This interaction could be reversed using cationic surfactants 
(Figure 1.3b), which restored ChT activity.29 Based on the DLS data, two distinct 
mechanisms for this reversal were postulated: alkyl surfactants 3 and 4 form a bilayer 
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structures, whereas cationic thiol 5 and alcohol 6 directly modify the monolayer to 
liberate the bound proteins. 
 
Figure 1.3: Protein-nanoparticle conjugation and the applications. (a) Electrostatic 
targeting of ChT by anionic NP 3 b) Complexation of ChT with anionic nanoparticle and 
its release mechanisms by addition of various surfactants. c) Different degrees of 
restoration of enzymatic activity of nanoparticle-bound ChT by addition of various 
positively charged surfactants. (d) Specific interaction of biotin functionalized 
nanoparticles with streptavidin. (e) Structure of NTA-modified magnetic nanoparticles. 
(f) The NTA-Ni2+ functionalized magnetic nanoparticles selectively bind to histidine-
tagged proteins. 
 
The use of simple alkyl-based monolayers resulted in protein denaturation, an 
unfavorable outcome for a number of applications in delivery and biotechnology. Relying 
on the resistance of OEG to nonspecific interactions with biomolecules,30 tetra(ethylene 
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glycol) spacers were introduced at the nanoparticle-protein interface.31 Structural data 
obtained from fluorescence and CD studies revealed that the nanoparticle-bound ChT 
maintained its native structure. Further studies demonstrated that nanoparticle-protein 
complexation can considerably stabilize the bound proteins against denaturation at the 
air-water interface.32 
Specific biomacromolecular interactions, such as streptavidin/biotin 
complementarity (Ka ~ 1014 M-1),33 have been used to provide specific protein-NP 
binding. Zheng and Huang introduced biotin and glutathione-functionalized gold 
nanoparticles functionalized with tri(ethylene glycol)-terminated thiols.34 These particles 
bind specifically to streptavidin and glutathione-S-transferase, respectively, to give stable 
complexes with minimal nonspecific binding with other proteins (Figure 1.3d). Biotin 
functionalized QDs were also used for specific protein binding in time-resolved 
fluoroimmunoassay.35 Another way to specifically bind proteins is through the use of 
transition metal complexes that bind with surface-exposed histidines of proteins.36 Xu et 
al. fabricated FePt nanoparticles (magnetic, NP 7), with nickel-terminated nitrilotriacetic 
acid (NTA).37 These NPs show high affinity and specificity towards histidine-tagged 
proteins (proteins with six consecutive histidines residues) (Figure 1.3e). In comparison 
to commercial magnetic microbeads, these NPs have a large protein binding capacity due 
to their high surface/volume ratio. This concept can be employed to manipulate the 
histidine-tagged recombinant proteins and bind other biological substrates at low 
concentrations.38,39 
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1.3 Nanoparticles as Drug Delivery Systems 
Drug delivery systems (DDSs) can improve several crucial properties of ‘free’ 
drugs, such as solubility, in vivo stability, pharmacokinetics and biodistribution, thus 
enhancing their efficacy.40 In a recent example of cellular delivery, mixed monolayer 
protected gold clusters were exploited for in vitro delivery of a hydrophobic fluorophore 
(BODIPY); an analog of hydrophobic drugs.41 The cationic surface of the nanoprticles 
facilitated the penetration of cell membrane, and payload release was triggered by 
intracellular glutathione (GSH), relying on the ~1000-fold higher intracellular 
concentration of GSH relative to the extracellular environment (Figure 1.4a). Release of 
the dye was established by fluorogenesis upon release of the dye from the nanoparticle 
(Figure 1.4b,c). The controlled release of the fluorophore was observed in mouse 
embryonic fibroblast (MEF) cells, containing ~ 50% lower GSH levels than Hep G2, 
through incubation with glutathione monoethyl ester (GSH-OEt), which is processed to 
GSH by esterases for transiently increasing intracellular GSH concentrations (Figure 
1.4d).  
 
Figure 1.4: a) Schematic illustration of GSH-mediated surface monolayer exchange 
reaction/payload release. b) in cuvette release of BODIPY ligand mediated by GSH. c) 
  8
The bright field and fluorescence images of Human Hep G2 cells incubated with AuNP 
for 96 hours. d) Fluorescence images of MEF cells displaying GSH controlled release of 
the fluorophore after incubation with of 0, 5, and 20 mM GSH-OEt. 
 
Lin et al. have demonstrated that thiols, such as dihydrolipoic acid (DHLA) and 
dithiothreitol (DTT), can likewise act as stimuli to remove pore caps in mesoporous silica 
nanoparticles, releasing trapped molecules inside the pores.42,43 The pores were capped 
with removable CdS or Fe3O4 nanoparticles through disulphide linkers that are 
selectively cleaved in a reducing environment. Release of encapsulated-FITC from 
magnetic nanoparticle-capped MCM-41 was observed in cancer cells due to the presence 
of a significant amount of intracellular DHLA.  
pH-responsive nanomateials provide an alternate mechanism for release, relying 
on the relatively acidic condition inside tumor and inflamed tissues (pH ~ 6.8), and 
cellular compartments including endosomes (pH ~ 5.5-6) and lysosomes (pH ~ 4.5-5.0).44 
Toward this end, magnetic nanoparticles (Fe3O4) were covalently functionalized with 
doxorubicin (DOX), an anticancer drug, through an acid labile hydrazone linker.45 The 
carrier was then encapsulated with a thermosensitive polymer for temperature controlled 
release of the drug. The hybrid system released DOX efficiently in mild acidic buffer 
solution of pH 5.3. Schoenfisch et al. have likewise shown that nitric oxide (NO) can be 
efficiently released at acidic pH from gold nanoparticles.46 
Besides the surface chemistry of nanoparticles, the unique physical properties of 
nanoparticles have been utilized in the design of DDSs. Ford et al. have designed a 
water-soluble nanocontainer for NO storage based on electrostatic assembly of DHLA-
coated quantum dots and cationic dinitro complexes that uses energy transfer from the 
core to release NO.47 In another approach, doping of Ag/Au nanoparticles serves as an 
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antenna to absorb the energy from a laser beam of ‘biologically friendly’ near-infrared 
(NIR) region causing local heating and disruption of microcapsules. More recently, 
Bhatia et al. designed multifunctional superparamagnetic nanoparticles for remote release 
of bound drugs (Figure 1.5).48 The particles transduce external electromagnetic force 
(EMF) at 350–400 kHz into local heating for melting DNA duplexes.  
 
Figure 1.5: Controlled release of payloads using oligonucleotide-modified iron oxide 
nanoparticles for drug delivery at a remote location (ref. 48). 
 
 
1.3.1 Nanoparticles as Delivery Vehicles of Biomolecules  
Nanoparticles can provide effective carriers for biomolecules such as DNA, RNA, 
or protein, protecting these materials from degradation and transporting them across the 
cell-membrane barrier. ‘Safe’ delivery of these biomolecules provides a means of gene 
therapy as well as protein-based therapeutic approaches. Gene delivery vectors were 
designed using a series of cationic nanoparticles with different positive charge coverage 
and hydrophobicity.49 In this study, NPs were incubated with a DNA plasmid encoding 
for β-galactosidase and then used to transfect embryonic kidney cells. Maximizing 
hydrophobicity without causing precipitation was found to play a key role in enhancing 
efficiency (Figure 1.6a-c). Building upon these studies, Klibanov et al. covalently 
  10
attached 2 kDa polyethylenimine (PEI2) onto the surface of gold nanoparticles.50 The 
transfection efficiency of these systems varied with the PEI to gold molar ratio in the 
conjugates, with the best conjugate being 12 times more potent than the unmodified 
polycation. The efficiency of the delivery could be doubled by the addition of the N-
dodecyl-PEI2 to the conjugate during complex formation, a further demonstration of the 
role of hydrophobicity in facilitating transfection. Lin et al. have recently reported 
mesoporus silica nanoparticles (MSNs)-mediated delivery of DNA into plants.51  
 
Figure 1.6: a) Structures of nanoparticles used for transfection by Rotello. b) β-
Galactosidase transfection using various nanoparticle-DNA complexes at 2200:1. c) 
Transfection efficiency of nanoparticles 9, 10, 11 (2200:1 nanoparticle/DNA ratio) and 
PEI (60 kDa). All transfections were performed in the presence of 100 µM chloroquine 
and 10% serum.  
 
In contrast to polycation-mediated transfection, cellular internalization of 
oligonucleotide functionalized gold nanoparticles carrying high negative surface potential 
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has emerged as a new approach to gene therapy.52 Antisense nanoparticles (ASNP) were 
effective at low concentrations to suppress EGFP translation in C166 cells. Investigation 
on the mechanism of cellular uptake of ASNP revealed that endocytosis is initiated by 
adsorption of a large number of serum proteins onto the particle surface.53   
We have functionalized the monolayer of gold nanoparticles with a photo-
cleavable o-nitrobenzyl ester moiety that dissociates upon light irradiation to alter the 
surface potential from positive to negative, thereby releasing adsorbed DNA (Figure 
1.7a),54 as established in cuvette by a T7 RNA polymerase assay (Figure 1.7b). FITC-
labeled DNA was successfully delivered into mammalian cells with nuclear localization 
of the released DNA ( Figure 1.7c,d), an important requirement for genetic therapy. 
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Figure 1.7: a) Depiction of photo-triggered release of DNA inside living cells. b) 
Illustration of light-induced surface transformation of nanoparticles. c) Fluorescence and 
bright field micrographs of cells after photo irradiation. To clarify the overlap of F-DNA 
and nuclei stain DAPI; green (Fluorescein) and blue (DAPI) channel are depicted with 
red and yellow color, respectively. d) Confocal microscopy images illustrating that the 
photo-released DNA accumulates inside the nucleus. Panel 1, 2, 3 and 4 show four 
consecutive slices of middle sections of z-series confocal images (Interval= 1.0 µm). 
 
RNA technology has emerged as a potential tool for curing disease at an early 
stage. A small interfering RNA (siRNA), generally consisting of 19-21 base pairs, can 
efficiently silence expression of a gene of interest. For in vitro delivery, siRNA has been 
conjugated to variety of nanoparticles, such as gold,55 quantum dots,56 or iron oxide,57 
with a thiol linker. Moore et al. has designed a multi-functional superparamagnetic 
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nanoparticle that can: (1) carry the siRNA, (2) deliver it in a site-specific manner, and (3) 
probe the delivery by magnetic resonance and optical imaging.57 The multifunctional 
nanoparticle was effective for in vitro and in vivo gene silencing via a specific pathway.   
Protein delivery is complementary to nucleic acid therapies in the field of 
biomedicine. As described in section 1.2, nanoparticles can efficiently bind to proteins, 
and hence can be used as protein delivery systems. Lin et al. have fabricated MCM-41 
type mesoporous silica nanoparticles (MSN) as protein carriers (Figure 1.8a).58 These 
MSN particles can incorporate cytochrome c, a membrane-impermeable protein, into 
their large pores (diameter = 5.4 nm), and can slowly release the proteins in active form 
under physiological conditions.  
 
Figure 1.8: Schematic illustration of cellular delivery of cytochrome c using mesoporous 
silica nanoparticles.  
 
1.4 Dissertation Overview 
The monolayer structure and peripheral groups of nanoparticles (NPs) play crucial 
roles for their potential applications in therapy, sensing and imaging. During my PhD 
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work, I designed and synthesized functional particles and studied their interactions with 
biomolecules. These studies provided a background for using nanoparticles in delivery 
applications. 
1.4.1 Functionalized Gold Nanoparticles for Surface Recognition  
Protein and Peptide Surface. Disruption of protein-protein interactions through 
surface recognition using synthetic scaffolds provides a powerful tool for biomedical and 
clinical applications. In a model study, we aimed to interrupt the cytochrome c-
cytochrome c peroxidase (Cyt c-CCP) binary adduct, which is formed mainly by ion-
pairing at the interface.59 To this end, cationic, anionic and neutral particles were 
synthesized. The functionalized nanoparticles interacted with proteins more strongly 
compared to the protein-protein interaction and bound selectively to either Cyt c or CCP 
based upon charge complementarity (Figure 1.9a and CHAPTER 2). The ubiquitous 
nature of protein-protein interactions based on α-helix recognition has contributed to the 
great interest in designing α-helix mimics as therapeutic modalities. We have 
demonstrated the nanoparticle-promoted folding of an anionic coiled-peptide into an α-
helix in completely aqueous media. The strategy was to allow favorable electrostatic 
interactions between the nanoparticle and the peptide when the negatively charged 
residues were positioned in a cofacial manner along the helix. The monolayer was 
tailored via incorporation of tetraethylene glycol (TEG) unit to prevent non-specific 
interactions and the surface was decorated with trimethyl ammonium as an electrostatic 
recognition unit (Figure 1.9b and CHAPTER 2).60  
DNA surface. DNA binding scaffolds are useful as gene regulators and 
transfection vectors. A library of nanoparticles functionalized with various amino acids 
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was fabricated for use in investigating the effects of different non-covalent interactions at 
the nanoparticle-DNA interface (Figure 1.9c and CHAPTER 3). This study indicated that 
particles with basic side chains interacted with DNA stronger than hydrophobic ones.61  
Cell surface. A series of nanoparticles were synthesized and their cellular uptake 
efficiency was assessed.62 Furthermore, in this study a method was developed for quick 
determination of cellular uptake of functionalized particles (Figure 1.9d and CHAPTER 
4). The method was based on laser desorption/ionization mass spectrometry (LDI-MS). 
In this technique, the gold cores facilitated ionization of attached ligands whose mass-to-
charge ratios (m/z) acted as “mass barcodes”. This barcode technique allowed 
identification of a specific particle in presence of another. After treating cells with even 
four different NPs simultaneously, the relative uptake of individual particles was 
successfully quantified, demonstrating multiplexed screening ability of this method. 
 
Figure 1.9: Functionalized gold nanoparticles for surface recognition. (a) Functionalized 
particles for effective recognition of protein surface and disruption of CCP:Cyt c couple. 
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(b) Nanoparticle-induced folding of a random coil peptide into α-helix in completely 
aqueous media. (c) Amino acid NPs and ammonium NPs to probe nanoparticle-DNA 
interactions. (d) Cellular uptake of functionalized nanoparticles. The TEM image 
showing cellular internalization of NPs. 
 
 
1.4.2 Nanoparticles-Mediated Delivery of Therapeutics  
DNA delivery. Transfection vectors were designed by varying the charge density 
on particle surfaces (Figure 1.10a and CHAPTER 5).63 Efficient gene delivery was 
observed using lysine and lysine dendron functionalized particles without any apparent 
cytotoxicity. These amino acid-based nanoparticles were responsive to intracellular 
glutathione levels, providing a tool for controlled release and concomitant expression of 
DNA. 
Protein delivery. In designing a vector for protein delivery, a peptide was tagged 
on the periphery of particles for protein recognition and subsequent cellular entry (Figure 
1.10b and CHAPTER 6). These particles promoted intracellular delivery of β-
galactosidase, a membrane-impermeable protein with high molecular weight (465 kDa).64 
Furthermore, these particles were able to transport functional proteins into a diverse array 
of cell lines and showed no obvious cytotoxicity. 
Drug delivery. Zwitterionic gold particles were fabricated as a nanocarrier for 
small molecule drugs (Figure 1.10c and a brief discussion in CHAPTER 7).65 We 
demonstrated that hydrophobic drugs and dyes could be encapsulated into hydrophobic 
pocket of NPs and stable nanoparticle-drug conjugates formed. The encapsulated drugs 
were released into cells via cell membrane mediated transportation. The released drug 
decreased the cell viability as expected, however, the particles were largely excluded 
from the cell body. 
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Figure 1.10: Functionalized gold nanoparticles for delivery applications. (a) Cationic 
nanoparticles condensed a large DNA into nanoplex and the complex efficiently 
transfected cells. (b) Peptide coated nanoparticles bound with proteins and showed 
protein transduction into mammalian cells. (c) Zwitterionic particles as a nanocarriers of 
hydrophobic drugs. 
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 CHAPTER 2 
NANOPARTICLE-PROMOTED FOLDING OF A RANDOM-COIL PEPTIDE 
INTO AN α-HELIX 
 
2.1 Introduction 
Protein-protein interactions are central to a number of cellular processes, such as 
signal transduction, cell adhesion, transcription and translation.1,2,3 Disruption of their 
interactions by specific recognition using synthetic scaffolds provides a potent tool in 
biomedical and clinical applications.4 In collaboration with the Knapp group (UMASS-
Amherst), we have shown the ability of nanoparticles to interrupt protein-protein 
interactions targeting the cytochrome c-cytochrome c peroxidase (Cyt c-CCP) adduct as a 
model system (Figure 2.1).5 The formation of this adduct is primarily driven by charge-
pairing at the interface between basic Cyt C (pI = 10.3) and acidic CCP (pI = 5.3). The 
functionalized nanoparticles interacted with proteins more strongly compared to the 
protein-protein interaction and bound selectively to either Cyt c or CCP based on charge 
complementarity. We have published this work in Chemical Communications (2006, 
1390-1392). 
 
Figure 2.1: A schematic representation of effective recognition of protein surface and 
disruption of CCP:Cyt c adduct using functionalized particles. 
Protein-protein interactions are site-specific and dictated through both non-
covalent interactions and shape complementarity.6 In several cases, the exposed face of a 
  23
helical segment interacts with another helical surface or a shallow cleft of the binding 
partner.4 For example, hydrophobic residues on the helical surface of p53, a tumour 
suppressor, bind to a deep hydrophobic cleft of MDM2, an oncoprotein, via steric 
complementarity.7 Therefore, the targeting of α-helices provides a promising tool for 
therapeutics.8 
A short peptide fragment is very susceptible to proteolytic cleavage and also lacks 
appreciable secondary structure. The resistance to proteolytic cleavage can be improved 
by chemical modifications including amidation of the carboxy terminus and acylation of 
the amino terminus, or by incorporation of non-natural amino acids, such as D-amino 
acids and β-amino acids.9,10 In general, the targeted peptide is designed such that the 
recognition units are positioned at alternating i, i + 3, i + 4 residues of the peptide 
backbone. Several synthetic strategies have been successfully developed to stabilize short 
peptides into α-helices. The strategies include the use of metal ion,11 cyclodextrin 
dimers12 and tetraguanidinium-based receptors.13 However, significant stabilization of 
peptide α-helices by synthetic scaffolds in completely aqueous media is a challenging 
task.14,15,16   
Nanoparticles offer a unique scaffold for biomolecule recognition by proper 
surface functionalization.17,18,19 In preliminary studies we used trimethylammonium 
functionalized gold nanoparticles to stabilize a tetraaspartate peptide (TAP) into an α-
helix in completely aqueous media.20 These particles, however, are not biocompatible.  
Incorporaton of a tetra(ethylene glycol) (TEG) unit renders access to a biocompatible 
nanoparticle through: (a) increasing the water solubilty,21 (b) prevention of non specific 
interactions with biomolecules,22 and (c) controlled surface recognition.23 In this chapter, 
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we have demonstrated stabilization of a peptide into an α-helix by functionalized 
nanoparticles with a TEG corona (Figure 2.2). Surprisingly, despite the highly flexible 
structure of the sidechains, these particles display templation to their peptide guests. 
These results have been reported in Chemical Communications (2007, 2796-2798). 
 
 
Figure 2.2: (a) Amino acid sequence of the target peptide. (b) End and side view of the 
tetraaspartate peptide. (c) Schematic depiction of the peptide binding in helical 
conformation on MMPC surface (shown in relative sizes). 
 
 
2.2 Results and Discussion 
The 17-amino acid peptide TAP was engineered such that four aspartate residues 
were placed at alternating i, i+3, and i+4 positions in order to orient them in one face 
once the peptide would fold into α-helix (Figure 2.2). The ends of the peptide were 
capped by acetylation of the amino terminus and amidation of the carboxy terminus to 
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decrease helix macrodipole effect. Moreover, a tryptophan (trp) residue was integrated at 
the N-terminal as a fluorescent probe. 
Cationic gold mixed monolayer protected clusters (MMPCs) with 2 nm core were 
used to induce folding of the negatively charged peptide TAP into an α-helix. A series of 
nanoparticles bearing different charge densities on the surface were fabricated (Table 
2.1). MMPC 1 – 3 were synthesized via Murray place exchange method24 by adding 
different ratios of two ligands, cationic TEG--trimethyl ammonium (TTMA) and neutral 
TEG-hydroxy (TOH). Water-soluble MMPC 4 was prepared according to the literature 
procedures.21 
Table 2.1: The series of nanoparticles used in this study and the percent of their cationic 
charge density. 
 
Nanoparticles TTMA : TOH % of cationic charge 
MMPC 1 1 : 0 ~ 100 
MMPC 2 1 : 0.43 ~ 70 
MMPC 3 1 : 0.78 ~ 55 
MMPC 4 0 : 1 0 
 
The ability of MMPC 1 to induce helicity was monitored in aqueous solution (pH 
11) using circular dichroism (CD). Varying concentrations (0 – 10 µM) of nanoparticle 
were mixed with 15 µM peptide solution, and CD spectra were collected after incubation 
for 5 min. CD spectra showed significant increase in helicity (maximum at 192 nm, 
minima at 208 nm and 222 nm) of the peptide in presence of the nanoparticle (Figure 
2.3). The percent of helicity induction was calculated by curve fitting using 
DICHROWEB. The overall helicity was obtained by combining the regular helix and 
distorted helix. In the absence of nanoparticle, the peptide was in a random coil 
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conformation showing only ~3% of helicity. Upon addition of cationic MMPC 1 to the 
peptide solution, there was substantial degree of stabilization in helical conformation with 
maximum overall helicity up to ~80% (Figure 2.4).  
 
Figure 2.3: CD spectra of the peptide (15 µM) after adding MMPC 1 of various 
concentrations in water (pH 11). 
 
 
 
Figure 2.4: DICHROWEB analysis of the CD spectra. 15 µM peptide was titrated 
against MMPC 1 in pH 11 water: increase in overall helicity (regular and distorted) with 
increase in nanoparticle concentration. 
 
 
In contrast, neutral particle (MMPC 4) was unable to induce helicity in the 
peptide, which signifies that the recognition of peptide by nanoparticle receptor is due to 
charge pairing (See control in Figure 2.3). Likewise, addition of salt to the mixture of 
MMPC 1 and peptide disrupted their interaction resulting in a sharp decrease in helicity 
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(Figure 2.5), validating electrostatic self-assembly. The electrostatic interaction between 
particle and peptide was regulated by using MMPCs with different cationic charge 
density on the surface. CD experiments were performed to observe the effect of charge 
density on helicity induction. The spectra were obtained after incubation of each of these 
particles (6 µM) with 15 µM of peptide solution for 5 min and a pronounced change in 
helicity was observed (Figure 2.5). As expected, helicity decreases with decrease in 
charge density on the particle surface. 
 
Figure 2.5: (a) CD spectra of a mixture of 15 µM peptide and 6 µM of MMPC 1 at 
different salt concentration. (b) Calculated overall helicity (regular and distorted) of 15 
µM peptide in presence of 6 µM MMPCs in water of pH 11.  
 
The binding affinity of the peptide with MMPCs 1-3 was further investigated by 
fluorescence. Trp-fluorescence was monitored by adding increasing amount of 
nanoparticle to the 2 µM peptide solution. Upon binding with the peptide, MMPCs 
quenched the fluorescence due to the gold core. The corrected fluorescence intensities (I / 
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I0) were plotted against nanoparticle concentration and fitted with the binding equation 
(Figure 2.6). The calculated macroscopic binding constant (Ks) were similar for all of the 
cationic particles (Table 2.2) with ~5-6 peptides binding per particle. The results reflect 
that the energy required for conformational change is balanced by the favorable enthaply 
change due to ionic interaction.  
 
 
Figure 2.6: Binding curves of 2 µM peptide with different MMPCs from fluorescence 
titration in pH 11 water. Absorbance of nanoparticles was corrected using neutral  
MMPC 4. 
 
Table 2.2: Calculated macroscopic binding constant (Ks), Gibbs free energey change      
(-∆G), and binding ratio (n) for the complexation between peptide and cationic 
nanoparticles in pH 11 water, as determined via fluorescence (The error in binding 
constants and binding ratios were 25% and  5%, respectively).  
 
 
Nanoparticles Ks / 106 M-1 -∆G / kJ mol-1 n 
MMPC 1 4.1   38.4 5.1 
MMPC 2 2.1 36.7 6.7 
MMPC 3 2.9 37.5 4.7 
 
   
Gold colloids have the ability to template through maximization of binding 
enthalpy as the thiols are mobile on the self assembled monolayer (SAM) surface.20,25 To 
determine if this was occurring with our particles, the peptide was incubated in the 
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presence of MMPCs over a period 24 h. As expected, no templation was observed in the 
case of MMPC 1 due to the complete coverage by the functional group. Significantly, 
MMPC 2 showed a 16% increase in helicity within a period of 24 h presumably due to 
the mobility of the ligands on the nanoparticle surface (Figure 2.7). Further decrease in 
the density of recognition unit for MMPC 3 resulted in no templation. This lack of 
templation presumably arises from the low concentration of ligands on the surface, 
increasing the entropic cost of templation. 
 
Figure 2.7: Particle-assisted templation of peptide: increase in helicity of TAP with time 
on incubation with MMPC 2. 
 
2.3 Conclusion 
In summary, we have demonstrated stabilization of α-helices using nanoparticles 
featuring flexible TEG-terminated sidechains. The electrostatic interaction and hence the 
extent of helicity induction can be tuned by tailoring the monolayer of MMPCs. Finally, 
despite the high flexibility of the ligands, MMPC 2 shows templation of the particle 
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surface to the peptide. In addition to providing enhanced binding and helicity for target 
peptides, the observed templation highlights the preorganized nature of the nanoparticle 
monolayer. Clearly, structural information is transmitted via the highly flexible ligands 
from the particle surface to the terminus, a distance of ~ 3 nm.26 The nature of this 
monolayer organization is an open question that a number of groups are exploring,27,28 
providing important insight for both pragmatic and fundamental purposes.     
 
2.4 Experimental Section 
General: All the reagents were purchased from Aldrich and used as received. All 
the recognition experiments were carried out in miliQ water of pH 11. Concentrations of 
the peptide and particle stock solutions were measured by UV.   
Synthesis of ligands: Both the thiol ligands, teghydroxy (TOH) and tegtrimethyl 
ammonium (TTMA), were synthesized according to the literature procedure.29,5  
Synthesis of MMPC 1 - 3: 1-pentanethiol-capped gold nanoparticles were 
dissolved in dichloromethane (DCM) and the ligands were dissolved in DCM alone (for 
MMPC 1) or 1:1 DCM-methanol mixture (for MMPC 2 and 3). Both the solution of 
particles and ligands were purged with argon separately for 30 min. Then two solutions 
were admixed and stirred at room temperature for ~ 48 h. MMPC 1 was precipitated out 
from the solution, while MMPC 2 and 3 remained in solution. In order to remove free 
ligands, MMPC 1 was washed five times with DCM by centrifugation, and MMPC 2 and 
3 were dialyzed in distilled water for a day. The particles were dried and dissolved in 
D2O to acquire NMR spectra. The percentage of cationic charge was calculated by NMR 
end group analysis.  
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Synthesis of peptide: The tetraaspartate peptide, TAP, was synthesized using the 
Fmoc chemistry-based solid-phase peptide synthesis technique. The crude peptide was 
purified by reverse-phase HPLC, and subsequently characterized by ESI mass 
spectrometry (M.W. = 1672.6).  
Circular dichroism experiments: 15 µM of peptide with various concentrations 
of nanoparticles were taken in a quartz cuvette with a 1-mm path length and placed on a 
Jasco 720 spectrophotometer.  After 5 min of equilibration at 23 ºC, CD spectra were 
acquired by scanning from 250 nm to 190 nm. Average of five scans was recorded at a 
rate of 20 nm/min with a sample interval of 0.1 nm and 8 sec response. The final spectra 
were obtained by subtracting the blank one and it was fitted into secondary structure 
algorithm CDSSTR (protein ref. set 7 comprising of 49 proteins) using DICHROWEB 
(http://www.cryst.bbk.ac.uk/cdweb/html/home.html). Neutral (TEG-OH) nanoparticle 
was used for the control experiment.                   
Fluorescence experiments: Fluorescence spectra were measured in a 1 cm quartz 
cuvette on a Shimadzu RF-5301 PC spectrofluorophotometer at 30 ºC. Trp fluorescence 
was monitored at 355 nm wavelength by exciting at 295 nm. 2 µM of peptide solution 
was titrated with MMPC 1 – 3 in milliQ water of pH 11. The quenching of Trp 
fluorescence by neutral MMPC 4 was measured to cancel the effect of absorption of 
nanoparticles. The corrected intensities were plotted against the nanoparticle 
concentration and fitted into a nonlinear least-squares curve-fitting equation30 using 
Origin 7.0 program (Origin Lab Co., Northampton, USA).  
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 CHAPTER 3 
AMINO ACID-FUNCTIONALIZED NANOPARTICLES AS DNA RECEPTORS 
 
3.1 Introduction 
Synthetic scaffolds that can recognize DNA effectively provide tools for treating 
various diseases of both genetic and acquired origin.1 These receptors can recognize 
DNA via electrostatic interaction, intercalation or major/minor groove binding, thus 
controlling multiple cellular processes, such as replication and transcription.2,3,4 
Additionally, such materials featuring high affinity towards DNA can also be potential 
transfection vectors for transporting genetic materials (e.g. plasmid DNA, siRNA or 
decoy DNA) into living cells in vitro and in vivo.5,6,7 
The large protein-DNA interface areas and the diversity of non-covalent 
interactions at the interface, such as electrostatic, hydrophobic, hydrogen-bonding and π-
π interactions must be considered when designing synthetic receptors for DNA 
recognitions.8,9 To this end, a variety of synthetic materials has been developed for DNA 
binding, including polymers,10,11 dendrimers12 and functional nanomaterials.13  These 
systems have been designed to bind DNA in either non-specific or specific fashion, thus 
modulating both the structure and function of bound DNA molecules.14,15 
 Gold nanoparticles provide an alternate scaffold for efficient DNA recognition, 
exploiting both the size and controlled surface functionality of these systems.16,17 In our 
earlier studies, we have demonstrated that trimethylammonium functionalized cationic 
nanoparticles bind with the phosphate backbone of DNA primarily through electrostatic 
interaction.18 The binding affinity was high enough to inhibit the transcription by T7 
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RNA polymerase in vitro.19 Moreover, these cationic nanoparticles facilitate transfection 
of DNA in mammalian cells.20  
In addition to the electrostatic interaction between cationic nanoparticles and the 
phosphate backbone of DNA, other non-covalent interactions should have an important 
impact on DNA binding.21 To explore the structural effects of the head groups on DNA 
binding, a library of cationic nanoparticles was fabricated via functionalization with 
naturally occurring L-amino acids (Figure 3.1). The structural diversity of amino acid 
side chains provides an additional handle to probe the effect of different noncovalent 
interactions in DNA binding. This study has been reported in Chemical Biology & Drug 
Design (2007, 70, 13-18).  
 
Figure 3.1: Schematic representation of (a) amino acid-functionalized nanoparticle and 
(b) interaction between DNA and amino acid-coated nanoparticle (drawn to scale). 
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3.2 Results and Discussion  
Fabrication of amino acid functionalized nanoparticles. In this study, a series 
of amino acid conjugated nanoparticles was synthesized to provide structural diversity on 
the particle surface.22 The structural diversity of these systems originates from the side 
chains of amino acids. The fabrication of nanoparticles was straightforward. The thiol 
ligands were synthesized in three steps with high yields (Figure 3.2). Trityl protected 
alcohol was prepared as the starting material for amino acid conjugation by reacting trityl 
thiol with 11-bromoundecanol. In the next step, the alcohol terminus was coupled to the 
free carboxylic acid of the boc-protected amino acid using DCC/DMAP. Deprotection 
was carried out using TFA/TIPS to simultaneously deprotect the thiol and amine groups 
at the termini of ligands. The thiols were incorporated onto the particle surface via the 
well known Murray place-exchange reaction with 1-pentanethiol coated gold 
nanoparticles (Figure 3.3).23  
 
Figure 3.2: Synthesis of amino acid conjugated thiol ligands. 
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Figure 3.3: Fabrication of amino acid coated cationic nanoparticles through a place-
exchange reaction.  
 
Fluorescence titration. Fluorescence titrations were carried out to investigate the 
binding between DNA and nanoparticles. A FITC-labeled 37-mer DNA was used for 
these studies: the sequence consists of a promoter region (17 bases) recognized by T7 
RNA polymerase and a template (20 bases) for RNA synthesis. Upon binding of the 
DNA to the particle surface, FITC-fluorescence was quenched due to energy transfer 
from the fluorophore to the gold core.17 The effect of nanoparticle absorbance on the 
emission intensity was corrected using a non-interacting neutral TEG-OH nanoparticle.22 
The corrected intensities were plotted against nanoparticle concentrations. The binding 
constants and the stoichiometries of nanoparticle-DNA complexation (binding ratios) 
were determined by non-linear curve fitting (Figure 3.4).22  
The calculated binding constants and binding ratios from the curve fitting are 
summarized in Table 3.1. Nanoparticles with cationic side chains have higher binding 
affinity for DNA compared to the nanoparticles bearing neutral hydrophobic side chains. 
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NP_L-Lys shows the strongest attraction towards DNA, ~ 3-fold higher than NP_L-Phe, 
the weakest one, indicating that the binding affinity can be varied moderately via 
functionalization of the nanoparticle surface. The trend in binding ratios indicates that the 
hydrophilic nanoparticles can accommodate more DNA on their surfaces than the 
hydrophobic particles. The results suggest that the electrostatic interaction dominates 
over hydrophobic interaction in nanoparticle-DNA interaction. Furthermore, we found 
that the chiral configuration of amino acid on nanoparticle surface does not influence the 
binding affinity towards DNA significantly (compare NP_L-Trp and NP_D-Trp in Table 
3.1). 
  
 
Figure 3.4: The binding curve of DNA (50 nM) with nanoparticles from fluorescence 
titration in 5 mM AcOH/NaOH buffer (pH = 5.0). 
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Table 3.1: The calculated binding constants (KS) and binding ratios (n) of DNA-
nanoparticle interaction from non-linear curve fitting. 
 
 
Circular dichroism. The conformational change of DNA upon interacting with 
the functionalized nanoparticles was investigated by circular dichroism. Recently, we 
have reported that quaternary ammonium-funtionalized nanoparticles change the CD 
signal of DNA to a substantial extent.24 Similarly, the amine-terminated cationic 
nanoparticles in this study (e.g. NP_L-Phe) distort the DNA secondary structure (Figure 
3.5a), as demonstrated by the decrease in ellipticity at 280 nm upon addition of 
nanoparticles. We continued our investigation on the structural changes of DNA with 
different amino acid-functionalized nanoparticles. CD spectra were collected after 
incubating DNA (0.25 µM) with amino acid functionalized nanoparticles. In the case of 
nanoparticles with hydrophobic side chains, the aromatic side chains (i.e. NP_L-Trp and 
NP_L-Phe) were found to unwind the DNA strand more effectively compared to the 
aliphatic sidechains (i.e. NP_L-Leu) (Figure 3.5b). This enhanced unwinding arises 
probably from π-π stacking of the aromatic rings on the sidechains with DNA bases.25 
For nanoparticles with hydrophilic side chains, NP_L-Arg perturbs the DNA structure 
more than NP_L-Lys (Figure 3.5c). This effect might be attributed to the possibility of 
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stable hydrogen bonding between the guanine moiety of arginine and interior DNA 
bases.26  
 
Figure 3.5: Circular dichroism spectra of 37-mer double stranded DNA (0.25 µM) in 
5mM AcOH/NaOH buffer (pH = 5.0). (a) Decrease in elipticity at 280 nm (θ280) upon 
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addition of cationic nanoparticles into DNA solution. Change in CD spectra of DNA by 
(b) hydrophobic nanoparticles and (c) hydrophilic nanoparticles ([NP] = 0.6 µM).  
 
3.3 Conclusion 
In conclusion, amino acid-functionalized gold nanoparticles provide a versatile 
scaffold for recognition of DNA. The binding affinity varies depending on the amino acid 
structure. Moreover, these nanoparticles perturb the DNA structure and the extent of 
unwinding depends on the amino acid sidechain. This study indicates that the efficiency 
of gene regulation or gene delivery can be modulated using this new class of 
nanoparticles featuring structural diversity.   
 
3.4 Experimental Section  
Materials. All chemicals were purchased from Aldrich and used as received. 
Solvents were bought from Pharmco-Aaper and used as received except dichloromethane 
and toluene which were distilled in presence of calcium hydride. The products were 
purified by column chromatography over silica gel (SiO2, particle size 40-63 µm). 
Fluorescein Isothiocyanate (FITC) labeled DNA was purchased from Integrated DNA 
Technologies (IDT). 
Ligand synthesis. Preparation of tritylmercaptoundecanol. A 60 ml solution of 
trityl thiol (13.2 g, 48 mmol) in 1:1 ethanol-benzene mixture was slowly added to a 
stirred solution (60 ml) of 11-bromoundecanol (10g, 40 mmol) in 1:1 ethanol-benzene 
mixture at room temperature. After cooling the reaction mixture to 0 °C, 10% aqueous 
NaOH solution (1.92 g, 48 mmol) was added into the flask and the reaction was 
continued overnight at room temperature. The solvents were removed in vacuo and 
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saturated sodium bicarbonate solution was added. The compound was extracted with 
dichloromethane. The organic layer was washed with brine, dried over anhydrous 
Na2SO4, and concentrated. The product was purified by flash column chromatography 
using a mixture of ethyl acetate and hexane (1:3, v/v) to afford the alcohol in 94% yield.  
General procedure for the conjugation of amino acids. The free carboxylic acid 
of boc-amino acid (1.38 mmol, e.g. 366 mg Boc-L-Phenylalanine) was activated using 
N,N′-dicyclohexylcarbodiimide (DCC, 285 mg, 1.38 mmol) and 4-(dimethylamino) 
pyridine (DMAP, 168 mg, 1.38 mmol) in 20 ml of dry dichloromethane at 0 °C. After 10 
min of stirring, the trityl protected alcohol (500mg, 1.12 mmol) was added. The reaction 
was continued overnight at room temperature. The white solid (dicyclohexylurea) was 
filtered out and the filtrate was washed with water. After evaporating the solvent, the 
residue was purified by flash chromatography on silica to yield the conjugated product 
(~70-85%).  
General procedure for deprotection. The amino acid conjugated product (1 mmol, 
e.g. 690 mg of Trityl-S-C11-Phe-Boc) was dissolved in 15 ml of dry distilled 
dichloromethane under argon. Addition of trifluoroacetic acid (TFA, 1.55 ml, 20 mmol) 
turned the solution yellow in color. The yellow color started to disappear after addition of 
triisopropylsilane (TIPS, 0.22 ml, 1.1 mmol). After 6 h, the reaction was quenched with 
water and extracted with dichloromethane. The organic layer was evaporated and the 
product was purified by column chromatography using 1:19 mixture (v/v) of methanol-
dichloromethane (L-Leu, L-Phe and D-/L-Trp) or washing with hexane and diethylether 
(L-Lys and L-Arg).  
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Nanoparticle synthesis. Amino acid functionalized nanoparticles. As a general 
protocol, 50 mg of 1-pentanethiol protected gold nanoparticles (Au_C5) and 100 mg of 
the thiol ligand were dissolved in dichloromethane in two separate vials. After purging 
both solutions with argon for 30 min, the ligand solution was poured into the particle 
solution. The place exchange reaction was continued for 48 h at room temperature. The 
amino acid-coated nanoparticles were precipitated out from the solution and the 
precipitate was purified by centrifugation using dichloromethane to remove the free 
thiols. NMR characterization of these particles in D2O showed a high exchange of the 
new thiol and absence of any free ligands. 
Au_TEG-OH. Tetraethylenglycol (TEG) coated neutral nanoparticle was prepared 
according to the literature procedure.27 
Fluorescence titration. Fluorescence titration was carried out in a 1 cm quartz 
cuvette on a Shimadzu RF-5301 PC spectrofluorophotometer at room temperature (ca. 25 
°C). FITC fluorescence of 50 nM DNA was monitored with addition of nanoparticle 
solution (4 µM NP + 50 nM DNA) in 5 mM AcOH/NaOH buffer (pH = 5.0) to ensure the 
complete protonation of amine groups on the particle surface. The fluorescence spectra 
were acquired from 490 nm to 600 nm after exciting the sample at 480 nm. The 
excitation and emission slit widths were 3 nm and 5 nm, respectively. 
Circular dichroism. Circular dichroism (CD) experiments were performed on a 
Jasco 720 spectrophotometer in a 1 cm quartz cuvette. CD spectra of 0.25 µM DNA were 
collected with addition of nanoparticle solution (40 µM NP + 0.25 µM DNA) in 5 mM 
AcOH/NaOH buffer (pH = 5.0). After 5 min of equilibration at 25 °C, the spectra were 
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recorded as an average of three scans from 300 nm to 240 nm with 16 sec response and 
10 nm/min scan rate. The final spectra were obtained after subtraction of the blank. 
37-mer DNA sequence. 
 
 
 
NMR data. In general, the proton (1H) NMR spectra of all compounds were 
taken in CDCl3 as a solvent in a 400 MHz NMR instrument. 
Tritylmercaptoundecanol: δ (ppm) 7.39 (m, 6H), 7.25 (m, 6H), 7.17 (m, 3H), 3.62 
(t, J = 7.4 Hz, 2H), 2.12 (t, J = 7.3 Hz, 2H), 1.53 (m, 2H), 1.37 (m, 16H). 
Trit-S-C11-L-Phe(Boc): δ (ppm) 7.40 (m, 6H), 7.25 (m, 9H), 7.18 (m, 3H), 7.12 
(m, 2H), 4.98 (br, 1H), 4.55 (m, 1H), 4.05 (t, J = 6.8 Hz, 2H),  3.06 (m, 2H), 2.11 (t, J = 
7.6 Hz, 2H), 1.56 (m, 2H), 1.40 (m, 11H), 1.24 (m, 14H). 
Trit-S-C11-L-Leu(Boc): δ (ppm) 7.40 (m, 6H), 7.25 (m, 6H), 7.19 (m, 3H), 4.85 
(br, 1H), 4.29 (m, 1H), 4.08 (t, J = 7.6 Hz, 2H),  2.12 (t, J = 7.2 Hz, 2H), 1.61 (m, 5H), 
1.42 (s, 9H), 1.25 (m, 16H), 0.93 (t, J = 3.2 Hz, 6H). 
Trit-S-C11-L-Trp(Boc): δ (ppm) 7.56 (m, 1H), 7.41 (m, 6H), 7.26 (m, 8H), 7.20 
(m, 4H), 7.10 (m, 1H), 5.08 (br, 1H), 4.64 (m, 1H), 4.04 (m, 2H), 3.28(m, 2H), 2.13 (t, J 
= 7.6 Hz), 1.52 (m, 4H), 1.42 (s, 9H), 1.21 (m, 14H). 
Trit-S-C11-D-Trp(Boc): δ (ppm) 7.56 (m, 1H), 7.41 (m, 6H), 7.27 (m, 8H), 7.20 
(m, 4H), 7.10 (m, 1H), 5.06 (br, 1H), 4.64 (m, 1H), 4.04 (m, 2H), 3.29(m, 2H), 2.13 (t, J 
= 7.6 Hz), 1.52 (m, 4H), 1.42 (s, 9H), 1.21 (m, 14H). 
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Trit-S-C11-L-Lys(Boc)2: δ (ppm) 7.40 (m, 6H), 7.28 (m, 6H), 7.20 (m, 3H), 5.10 
(br, 1H), 4.62 (m, 1H), 4.28 (br, 1H), 4.12 (t, J=6.4 Hz, 2H), 3.11 (m, 2H) , 2.13 (t, J = 
7.2 Hz, 2H), 1.82 (m, 2H), 1.56 (m, 2H), 1.55-1.16 (m, 38H). 
Trit-S-C11-L-Arg(Boc)2: δ (ppm) 7.40 (m, 6H), 7.28 (m, 6H), 7.20 (m, 3H), 5.40 
(br, 1H), 4.28 (m, 1H), 4.12 (t, J=6.4 Hz, 2H),3.90(m, 2H), 2.13 (t, J = 7.2 Hz, 2H), 1.82- 
1.16 (m, 40H). 
HS-C11-L-Phe: δ (ppm) 7.25 (m, 3H), 7.19 (m, 2H), 4.10 (t, J = 7.4 Hz, 2H), 3.73 
(m, 1H), 2.97 (m, 2H), 2.50 (q, 2H), 1.59 (m, 4H), 1.26 (m, 14H). 
HS-C11-L-Leu: δ (ppm) 4.13 (t, J = 7.6 Hz, 2H), 3.61 (t, J = 8.1 Hz, 1H), 2.52 (q, 
2H), 1.77 (m, 1H), 1.61 (m, 4H), 1.31 (m, 16H), 0.94 (t, J = 6.3Hz, 6H). 
HS-C11-L-Trp: δ (ppm) 7.62 (m, 1H), 7.35 (m, 1H), 7.12 (m, 3H), 4.08 (t, J = 7.6 
Hz, 2H), 3.83 (m, 1H), 3.13 (m, 2H), 2.51 (q, 2H), 1.60 (m, 4H), 1.26 (m, 14H). 
HS-C11-D-Trp: δ (ppm) 7.42 (m, 1H), 7.28 (m, 1H), 7.09 (m, 3H), 4.10 (m, 1H), 
3.96 (m, 2H), 3.35 (m, 2H), 2.51 (q, 2H), 1.56 (m, 4H), 1.32 (m, 14H). 
HS-C11-L-Lys: δ (ppm) 4.12 (m, 2H), 4.02 (m, 1H) , 3.03 (m,2H), 2.50 (m, 2H), 
1.90-1.16 (m, 24H). 
HS-C11-L-Arg: δ (ppm) 4.12 (m, 2H), 3.68 (m, 2H), 3.20 (m, 1H) ,2.50 (m, 2H), 
1.90-1.16 (m, 22H). 
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CHAPTER 4 
LASER DESORPTION/IONIZATION MASS SPECTROMETRY (LDI-MS): A 
NEW TOOL FOR SCREENING CELLULAR UPTAKE OF NANOPARTICLES  
 
4.1 Introduction 
Therapeutic nanocarriers carry drugs, genes, and/or imaging agents into cells and 
tissues of interests.1-4 Various materials, such as polymeric micelles,5 mesoporous silica 
nanorods,6 carbon nanotubes,7 and nanoparticles8-10 have been used as therapeutic 
nanocarriers, as well as probes for tracking intracellular processes. Effective use of 
nanoparticles as carriers and intracellular probes requires the ability to monitor these 
particles in cells, and several techniques are available for this purpose. These techniques 
can be classified into two groups: (1) label-free imaging techniques such as luminescent 
quantum dots imaging,10,11 atomic force microscopy (AFM),12 and transmission electron 
microscopy (TEM)13 and (2) barcoding techniques such as those that encode 
nanoparticles with fluorescence dyes that can be “read out” by a fluorescence 
spectrometer.2 Simultaneous screening of the cellular uptake of multiple particles with 
different surface functional groups, however, is a challenge for existing approaches. 
Here, we have described a new “mass barcoding” technique for monitoring the cellular 
uptake of multiple functionalized gold nanoparticles (AuNPs) by using laser 
desorption/ionization mass spectrometry (LDI-MS). 
Nanoparticles have been used in mass spectrometric analyses primarily to 
facilitate the laser desorption/ionization of compounds of interest. Tanaka et al14 showed 
that cobalt particles (~30 nm) suspended in glycerol facilitated the ionization of proteins. 
Subsequently, Ag,15 Au,16-22 C,23 and Si24,25 nanomaterials have been demonstrated as 
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LDI-MS matrices with different degrees of success. Meanwhile, some mass spectrometric 
work has also been devoted to the analysis of nanoparticles themselves. For pure samples 
of gold nanoparticles, electrospray ionization mass spectrometry (ESI-MS)26,27 and LDI-
MS28,29 have been used to measure the compositions of surface functionalities and atom 
numbers in the NP core.  
In this study, we tagged AuNPs with readily ionizable surface functionalities, i.e. 
“mass barcodes” (shown in Figure 4.1). These alkanethiolate cationic or neutral 
monolayers are barriers between the nanoparticle core and the environment, effectively 
protecting and stabilizing the gold cluster core in biological environments.30-32 Moreover, 
the chemical nature of these monolayers dictates interfacial interactions between cells 
and AuNPs, thus governing cellular uptake of AuNPs.33-35 Upon laser irradiation of these 
AuNPs, “mass barcodes” of alkanethiolate monolayers rather than the AuNPs 
themselves, can be simply “read out” by LDI-MS, thus providing characteristic peaks for 
identifying AuNPs. Ionization of alkanethiolate monolayers on flat gold surfaces has also 
been observed using LDI36,37 and matrix-assisted LDI (MALDI).38,39 The surface ligands 
on the AuNPs are primarily detected because the NP core efficiently absorbs the laser 
light (337 nm), and this energy is readily transferred to desorb and ionize the surface 
ligands, probably via a mechanism similar to that proposed by Tanaka.14 In this work, we 
investigated a potential advantage of such a “mass barcoding” approach – the ability to 
simultaneously analyze many different functionalized AuNPs. We predicted that each 
functionalized AuNP could be identified by its unique “mass barcode”. Furthermore, we 
explored this LDI strategy for direct analyses of AuNPs taken up by cells. Such a 
multiplexed screening of AuNPs could be very valuable for rapidly assessing the 
  50
chemical and physical parameters that influence AuNP uptake by cells. We have 
published these results recently in Journal of the American Chemical Society (2008, 130, 
14139-14143). 
 
Figure 4.1: Structural representation of the gold nanoparticles (AuNPs). The mass-
charge-ratios (m/z) attached to each AuNP act as “mass barcodes” used for identification 
of the AuNPs. 
 
 
 
Figure 4.2: (a) Schematic illustration of the analysis of the AuNPs in cell lysates by laser 
desorption/ionization mass spectrometry (LDI-MS). (b) Transmission electron 
microscopy (TEM) images of cellular uptake of AuNP 1.  
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4.2 Results and Discussion 
To explore the viability of “mass barcodes” for determining uptake efficiency of 
AuNPs, we cultured monkey kidney cells (COS-1) with AuNPs (500 nM) for 6 h (Figure 
4.2a). This concentration of AuNPs was non-toxic to the cells,40 and indeed after 6 h of 
incubation, no cell morphology change was observed. The cells were washed three times 
with cold phosphate-buffered saline (PBS) to remove extra AuNPs that were not taken up 
by the cells. Before lysing the cells, transmission electron microscopy (TEM) was used to 
verify the cellular uptake of AuNPs. As shown for a single cell (Figure 4.2b), a large 
amount of gold nanoparticles was trapped in vesicles (most likely via endosomal 
entrapment) in the cytoplasm, which was in agreement with results from other 
groups.13,41,42 It is possible that some AuNPs have escaped from the vesicles, and that 
depends on the NP surface functionalities.42,43 However, no such evidence was found in 
the TEM images. After the cells were lysed, the AuNPs taken up by the cells were 
collected as part of the precipitate after centrifugation of the lysate. The precipitate was 
subjected to LDI-MS, and spectra similar to that shown in Figure 4.3a were obtained. 
Figure 4.3a illustrates the characteristic peaks that were observed for AuNP 1. The 
spectrum of AuNP 1 showed an ion at m/z 422, which corresponds to the molecular ion 
(M+) of the ligand attached to AuNP 1. The spectrum also had a peak at m/z 388, which 
corresponds to [M-H2S]+, m/z 197 and 394, which correspond to Au+ and Au2+, 
respectively, and m/z 184, which corresponds to the head-group fragment of one of the 
most abundant lipids in animal cell membranes – phosphatidylcholine (PC). Moreover, a 
series of peaks spaced by 14 Da from m/z 262 to m/z 360 indicated successive losses of 
CH2 units from the alkyl chains of the surface ligands. Each of the other AuNPs in this 
  52
study had similar mass spectral patterns, with each AuNP featuring different m/z ratios 
allowing identification.  
The different “mass barcodes” of each AuNP facilitated multiplexed screening by 
LDI-MS. After simultaneously exposing cells to two different types of AuNPs, LDI-MS 
analysis of the resulting cell lysate indicated that both AuNPs can be readily identified. 
For example, in Figure 4.3b, diagnostic molecular ions at m/z 422 and m/z 436 indicated 
the cellular uptake of AuNP 1 and AuNP 2, respectively. Other characteristic peaks, such 
as [M-H2S]+ (m/z 388 for AuNP 1 and m/z 402 for AuNP 2), also assisted the 
identification of two AuNPs.  
 
Figure 4.3: LDI mass spectrum of COS-1 cell lysate after uptake of (a) AuNP 1 and (b) 
AuNP 1 and AuNP 2.  m/z 422 and m/z 436 correspond to the molecular ion (M+) of the 
ligands attached to AuNP 1 and AuNP 2, respectively; “*” is Au+ (m/z 197); “@” is Au2+ 
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(m/z 394); “#” is the molecular ion corresponding to the head-group fragment of 
phosphatidylcholine (m/z 184). 
  
Quantifying the relative cellular uptake of these two different AuNPs should be 
possible by comparing the ion abundances of their respective molecular ion peaks. To do 
so, however, the relative ionization efficiencies of the ligands in cell lysates must be 
considered. The ionization efficiencies of the surface ligands were investigated under two 
sets of control conditions. First, equimolar amounts of AuNP 1 and AuNP 2 (300 pmol 
each) were directly analyzed by LDI-MS, indicating that the ligands on AuNP 2 were 
ionized more readily as indicated by a molecular ion abundance ratio (AuNP 2/AuNP 1) 
of 1.79 ± 0.04. Then equimolar amounts of AuNP 1 and AuNP 2 (300 pmol each) were 
mixed with cell lysates and analyzed by LDI-MS, and again, the surface ligands on AuNP 
2 were more readily ionized, giving rise to a molecular ion abundance ratio (AuNP 
2/AuNP 1) of 1.41 ± 0.09 (Table 4.1). Since the data from the second set of experiments 
was more comparable to the cell uptake experiments, the ion abundance ratio of 1.41 can 
be used to determine the relative quantity of the AuNPs taken up by the cells.  After 
correcting the experimentally observed ratio of 1.70 ± 0.14 (Figure 4.3b and Table 4.1) 
by the ratio observed from the analysis of the cell lysates, the cellular uptake of AuNP 2 
was determined to be 1.21 (± 0.13) times greater than AuNP 1.  A similar analysis can be 
done for each of other AuNPs in comparison to AuNP 1 (Figure 4.4 and Table 4.1).  
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Table 4.1: LDI-MS relative quantification of cellular uptake of AuNPs (1-5). 
 
 
Mass barcodes 
(m/z) 
Control 
Ratioa 
Experimental 
Ratiob 
Relative 
Ratioc 
AuNP 2 / AuNP 1 436 / 422 1.41 ± 0.09 1.70 ± 0.14 1.21 ± 0.13 
AuNP 3 / AuNP 1 492 / 422 0.72 ± 0.08 0.40 ± 0.10 0.50 ± 0.20 
AuNP 4 / AuNP 1 465 / 422 0.19 ± 0.05 0.21 ± 0.03 1.10 ± 0.30 
AuNP 5 / AuNP 1 369 / 388 0.26 ± 0.05 0.09 ± 0.02 0.34 ± 0.09 
 
a
 300 pmol of each AuNP was mixed with 300 pmol AuNP 1 in lysed COS-1 cells and 
subjected to LDI-MS analysis. b300 pmol of each AuNP was mixed 300 pmol AuNP 1 
and then cultured with living COS-1 cells. These cells were then washed, lysed, and 
analyzed by LDI-MS. cRelative ratios are generated by comparing experimental ratios 
with control ratio.  
 
 
 
Figure 4.4: Relative quantities of the AuNPs in COS-1 cell lysates determined by LDI-
MS and ICP-MS. In both cases, the AuNP amounts are normalized to AuNP 1. 
 
The relative uptake amounts of each AuNP provided by the LDI-MS data were 
validated using inductively coupled plasma mass spectrometry (ICP-MS). ICP-MS 
provides high sensitivity and robustness for elemental analysis,13 but it lacks the capacity 
to identify AuNPs with different surface functionalities. So, the cellular uptake amounts 
of each AuNP had to be determined separately (see experimental section for details). The 
relative uptake amounts for each AuNP (compared to AuNP 1) as determined by ICP-MS 
(Figure 4.4) were very similar to the LDI-MS data, indicating that LDI-MS can reliably 
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provide the relative quantities of each AuNP taken up by COS-1 cells. Interestingly, the 
similarity of the ICP-MS data, which was acquired after uptake of individual AuNPs, and 
the LDI-MS data, which was acquired after uptake of two different AuNPs, indicated that 
interactions between the AuNPs in their cellular uptake were minimal. 
Taken as a whole, the quantitative data in Figure 4.4 indicated that AuNP 2 and 
AuNP 4 were more readily taken up by COS-1 cells than AuNP 3 and AuNP 5. The exact 
mechanism by which the AuNP were taken up by the cells is probably complex and is 
still an active area of investigation. Nonetheless, several factors have been recognized to 
govern the cellular uptake efficiency of nanoparticles, such as size,13,41 shape,13 and 
surface properties.12,33-35 Since the cell membrane is negatively charged, positively 
charged nanoparticles are generally found to have higher uptake efficiencies.33,35 So, it 
was perhaps not surprising that AuNP 5 with its neutral surface was less readily taken up 
by the cells than the cationic AuNP (1-4).33,35 While taken up more efficiently than AuNP 
5, the four cationic NPs (AuNP 1 through AuNP 4) all exhibited slightly different uptake 
efficiencies. From this limited set of AuNPs, it is difficult to conclude what other factors 
control uptake, but surface ligand hydrophobicity might be an important parameter. 
AuNP 3 was the most hydrophobic of the cationic AuNPs, and it was least efficiently 
taken up by the COS-1 cells. Obviously, more work is needed to better understand the 
effect of hydrophobicity on AuNP cell uptake, and this mass barcode approach along 
with LDI-MS detection will be helpful in this regard.  
To ensure that the results in Table 4.1 and Figure 4.4 do not simply reflect 
different AuNP stabilities in a cellular environment, the AuNPs were kept in cell lysate 
for different periods of time before analysis by LDI-MS. As an example, equal amounts 
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of AuNP 1 and AuNP 2 (300 pmol each) were incubated with cell lysate for different 
amounts of time, and the relative ratios between the two nanoparticles were found to 
remain steady for up to 24 hrs (Figure 4.5), which indicated that these two nanoparticles 
have essentially the same stability in the cellular environment.  
 
Figure 4.5: Stability of AuNPs in the cellular environment. Equal amounts of AuNP 1 
and AuNP 2 (300 pmol each) were incubated with cell lysate for different times. Relative 
ratios of AuNP 2/AuNP 1 were calculated by comparing intensities of m/z 436 and m/z 
422 in spectra.  
 
We also investigated the sensitivity of our LDI-MS approach by culturing COS-1 
cells with differing amounts of AuNPs.  We found that AuNPs present at levels as low as 
30 pmol (50 nM) in cell cultures could be readily detected. Figure 4.6 illustrates this for 
experiments with AuNP 1. The characteristic peak for AuNP 1 was readily apparent m/z 
422 with a signal-to-noise ratio of 75. With such good signal, we feel that the AuNPs 
could be detected even when present at even lower amounts. 
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Figure 4.6: LDI mass spectrum of COS-1 cell lysate after uptake of 30pmol AuNP 1 
(50nM AuNP 1 in 600uL culture solution). Peak m/z 422 has a signal-to-noise ratio 75.  
 
A key advantage of the LDI-MS measurements over the ICP-MS measurements 
or other measurements is the ability to simultaneously identify and quantitate the uptake 
of multiple AuNPs. To demonstrate the advantages of such a multiplexed analysis, COS-
1 cells were cultured with four cationic AuNPs (AuNP 1-4) (300 pmol each), and the 
resulting cellular contents were analyzed by LDI-MS (Figure 4.7a). Diagnostic molecular 
ions peak at m/z 422, m/z 436, m/z 492, and m/z 465 indicated the presence of AuNP 1, 
AuNP 2, AuNP 3, and AuNP 4 respectively. The relative quantities of each AuNP 
(Figure 4.7b) indicated that AuNP 2 was the most readily taken up by the cells, while 
AuNP 3 was the least readily taken up, quite similar to the results in Figure 4.4. The 
slight differences might be explained by an increase in the total amount of AuNPs present 
in the experiments. This increase may have caused uptake competition between the 
AuNPs, causing AuNP 4, for example, to be taken up less readily. 
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Figure 4.7: (a) Multiplexed LDI mass spectrum of COS-1 cell lysate with the four 
cationic AuNPs (AuNP 1-4). m/z 422, m/z 436, m/z 492 and m/z 465 correspond to 
AuNP 1, AuNP 2, AuNP 3, and AuNP 4, respectively; notations: “*”,”@”, “#” are same 
as in Figure 4.3. (b) Relative amounts of AuNPs (1-4) obtained from the LDI-MS. The 
AuNP amounts are normalized to AuNP 1. 
 
4.3 Conclusion 
In conclusion, we have described the use of AuNPs with mass barcodes for the 
multiplexed screening of AuNP cellular uptake. We demonstrated that the relative 
quantities of 4 different AuNPs taken up by cells can be simultaneously determined using 
LDI-MS with this approach. We also found that the cellular uptake of the functionalized 
AuNPs was dependent on NP surface functionality, suggesting that differential cellular 
uptake and cell-specific targeting might be possible if the appropriate surface 
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functionalities are chosen. In the future, we plan to use this technique to evaluate 
differential AuNP uptake by different cell states (e.g. normal and diseased). A future 
improvement will be to combine the LDI-MS approach with sub-cellular fractionation. 
This combination should be able to identify the intracellular targets for the AuNPs. On 
the whole, this LDI-MS technique has great potential for both the development of AuNP-
based delivery vectors and for probing transport of nanomaterials in vitro and in vivo. 
 
4.4 Experimental Section 
AuNP 1-5 synthesis. The Brust-Schiffrin two phase synthesis method31 was used 
for synthesis of AuNPs with core diameters around 2 nm. After that, the Murray place-
exchange method was used to obtain functionalized AuNPs 1-4 (Figure 4.8).30,32  AuNP 5 
was synthesized using one phase reduction method as reported.31 
 
 
 
Figure 4.8: General scheme for synthesis of cationic gold nanoparticles (AuNP 1-3). 
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Cell culture and cellular uptake of AuNPs. Monkey kidney COS-1 cells 
(75,000 cells/well) were grown on a 24-well plate in high-glucose Dulbecco’s Modified 
Eagle Medium (DMEM; glucose (4.5 gL-1)) containing 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (pH 7.4, 25 mM) supplemented with fetal 
bovine serum (FBS, 10%, Aldrich). Cultures were maintained at 37 °C under a 
humidified condition with 5% CO2. After 24 h of plating, the cells were washed once 
with cold phosphate-buffered saline (PBS), and the solutions of nanoparticles (Table 4.2) 
were added. Following 6 h of incubation, the cells were washed three times with PBS to 
remove extra nanoparticles and lysed for 15 minutes with a lysis buffer according to the 
kit from GENLANTIS. A quick freeze/thaw cycle (freeze 2 h at -20 °C then thaw at room 
temperature) was performed to improve lysis. The lysed cells were then prepared for 
LDI-MS or ICP-MS analyses. For screening of four cationic nanoparticles (AuNP 1- 4) 
simultaneously, the COS-1 cells were plated on a 6-well plate with (75000 × 4.8) 
cells/well. The cells were treated in manner similar to that mentioned above. A mixture of 
four AuNPs (Table 4.2) was added into each well and incubated for 6 h.  
Control experiments for quantification: COS-1 cells were first lysed, and then 
the solutions of nanoparticles in PBS only (Table 4.3) were added into each well and kept 
in the incubator for 6 h. The amount of nanoparticles and sample preparations were the 
same as described above except that no media was added. 
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Table 4.2: Gold nanoparticles solution preparation for cellular uptake of AuNPs. 
 
Nanoparticles Nanoparticles Solutions (Vol. and Conc.)/well 
(a) Individual AuNP 100 µl of 3 µM AuNP 
in PBS + 500 µl of 
DMEM 
600 µl  
500 nM AuNP 
(b) Mixture of two 
AuNPs (AuNP 1 with 
AuNP 2-5) 
50 µl of 6 µM NP 1 in 
PBS + 250 µl of 
DMEM 
AND 
50 µl of 6 µM NP 2or 
NP 3 or NP 4 or NP 5 
in PBS + 250 µl of 
DMEM 
600 µl 
 500 nM AuNP 1 AND 
500 nM AuNP 2 or AuNP 
3 or AuNP 4 or AuNP 5 
(c) Mixture of four 
AuNP  
(AuNP1-4)  
100 µl of 3 µM AuNP 
(1-4) in PBS + 500 µl 
of DMEM; then mix 
these four solution 
2.40ml  
125 nM AuNP 1 and 
AuNP 2 and AuNP 3 and 
AuNP 4 
 
 
Table 4.3: Gold nanoparticles solution preparation for control experiments for 
quantification 
 
Nanoparticles Nanoparticles Solutions 
(a) Mixture of two 
AuNPs (AuNP 1 with 
AuNP 2-5) 
50 µl of 6 µM AuNP 1 in PBS  
AND 
50 µl of 6 µM AuNP 2 or AuNP 
3 or AuNP 4 or AuNP 5 in PBS  
(b) Mixture of four 
AuNP  
(AuNP 1-4)  
100 µl of 3 µM AuNP (1-4) in 
PBS  
 
 
Cell TEM: Cells were treated with AuNP 1 (1µM NP of 600µl solution per well 
in a 24-well plate) and washed with PBS buffer after 6 hrs. Then cells were removed 
from the plate by trypsinization and centrifuged to collect a pellet. The pellet was fixed 
with 2% gluteraldehyde for 30 min and postfixed with 1% OsO4 for 1 hr. OsO4 is highly 
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poisonous and must be used with extreme caution! Following agarose (1.5%) enrobing, 
Spurr's resin embedding, and ultrathin (50 nm) sectioning, the samples were stained with 
2% aqueous uranyl acetate and 25 mg/ml lead citrate.  The image was taken under a 
JEOL 100S microscope. 
LDI-MS instrumentation: The sensitivity experiments were performed on a 
Waters Micromass M@LDI L/R mass spectrometer. All other LDI-MS analyses were 
done on a Bruker Reflex III time-of-flight mass spectrometer. The Bruker Reflex III is 
equipped with a 337-nm nitrogen laser, a 1.0-m flight tube, and a stainless steel sample 
target. All mass spectra were acquired in reflectron mode using a voltage of 16 kV. All 
reported spectra represent an average of 50 shots acquired at 90% laser power. The 
accelerating voltage was set to 20 kV. The Waters instrument was operated with positive 
reflection mode. Pulse voltage was set to 2400 V, source 15 000 V, MCP 1850 V. Matrix 
suppression delay was set to m/z 100. The spectrum represents an average of 50 shots 
acquired at 70% high laser power. 
LDI-MS sample preparation and measurements: The lysed cells were 
centrifuged at 14000 rpm for 10 min. AuNPs precipitated together with the cell lysates 
were washed with 60% acetonitrile/ 40% water, applied directly to a stainless steel target, 
and allowed to dry. The dry samples were washed again on the target with 60% 
acetonitrile/40% water and then allowed to dry before LDI analysis. Each AuNP 
experiment was performed in triplicate, and at least 5 spots of each replicate were 
measured by LDI-MS. 
ICP-MS Instrumentation: All ICP-MS measurements were performed on a 
Perkin Elmer Elan 6100. Operating conditions of the ICP-MS are listed below: RF 
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power: 1200 W; plasma Ar flow rate: 15 L/min; nebulizer Ar flow rate: 0.96 L/min; 
isotopes monitored: 197Au and 103Rh (as an internal standard); dwell time: 50 ms; 
nebulizer: cross flow; spray chamber: Scott. 
ICP-MS sample preparation and measurements: Each AuNP was incubated 
with COS-1 cells separately as described above (Table 4.2). After incubation and lysing 
the cells, the resulting cell lysate was digested overnight using 3 mL of HNO3 and 1 mL 
of H2O2. On the next day, 3 mL of aqua regia, which is highly corrosive and must be used 
with extreme caution, was added, and then the sample was allowed to react for another 1-
2 h. A hot plate (~100 °C) was used to reduce the above digested solution down to 1-2 
mL.  The concentrated sample solution was then diluted to 100 mL with de-ionized 
water, and aqua regia and a 103Rh internal standard solution were also added. The final 
AuNP sample solution contained 5% aqua regia and 10 ppb 103Rh. The AuNPs sample 
solution was measured by ICP-MS under the operating conditions described above. Cell 
uptake experiments with each AuNP were repeated 3 times, and each replicate was 
measured 10 times by ICP-MS. A series of gold standard solutions (20, 10, 5, 2, 1, 0.5, 
0.2, 0 ppb) were prepared before each experiment. Each gold standard solution contained 
5% aqua regia and 10 ppb 103Rh. Each standard solution was measured 10 times by ICP-
MS using the operating conditions described above. The resulting calibration line was 
used to determine the gold amount in taken up by the cells in each sample. A ~100 ppm 
solution of dithiothreitol was used to wash the instrument between analyses to facilitate 
gold removal.  
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CHAPTER 5 
EFFICIENT TRANSFECTION BY TUNING THE SURFACE CHARGE 
DENSITY OF AMINO ACID-FUNCTIONALIZED NANOPARTICLE VECTORS 
 
5.1 Introduction 
Gene therapy offers great promise for curing cancer and genetic disorders of both 
innate and acquired origin.1,2 Successful therapy requires the transport of nucleic acids 
into cells by delivery vehicles, as DNA is not efficiently translocated through the cell 
membrane.3 Recombinant viruses provide effective transfection vectors,4 however issues 
of immunogenicity, carcinogenicity and inflammation raise serious concerns for clinical 
applications.5,6,7 The challenges faced with viral vectors have inspired the parallel 
development of non-viral vectors based on polymers,8,9 dendrimers10,11 and 
liposomes.12,13 These synthetic systems, however, are less efficient than viral systems.14,15 
Therefore, efforts continue to focus on designing safe and efficient vectors.16  
Inorganic nanoparticles including silica,17 iron oxide18 and CdSe,19 have been 
exploited recently as alternate non-viral vectors. Gold nanoparticles provide particularly 
attractive scaffolds for the creation of transfection agents.20,21,22 Gold colloids are bio-
inert, non-toxic and readily synthesized and functionalized.23,24 They also provide a 
multifunctional platform for both therapeutic and diagnostic purposes.25,26,27,28 Finally, 
through proper functionalization, these particles can be engineered to accumulate 
preferentially at tumor sites using targeting ligands, providing a powerful tool for cancer 
gene therapy.29,30  
The use of these nanoparticles for DNA transfection has been described here. 
There are several challenges to the design of polycations for gene transfection, including 
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the need for effective complexation and condensation of the DNA, cellular uptake 
through endocytosis coupled with endosomal escape, protection from nuclease digestion 
in the cytoplasm, and finally delivery of the DNA to the nucleus.31 Nature provides 
insight into DNA packaging, where DNA wraps around histone octamers, the 
nucleosome core proteins ~6 nm in diameter featuring a large proportion of basic 
residues (lysine and arginine) that form salt bridges with the phosphate backbone of 
DNA.32 Using this structure as a starting point we designed DNA packaging agents using 
tiny spherical gold nanoparticles (core diameter ~2 nm, overall diameter 6 nm) featuring 
amino acids (Figure 5.1), which resemble histones in shape, size and surface 
functionality. In these studies we found that compaction of DNA can be improved by 
increasing the density of ammonium groups on the nanoparticle surface, which facilitated 
delivery. Conjugation of lysines on particles in a dendritic fashion yielded efficient 
vectors, ~28-fold higher than polylysine for in vitro transfections. Amino acid coated-
particles showed no cytotoxicity. Finally, the gold-thiolate binding of ligands to particles 
allowed the transfection ability of these materials to be regulated by manipulation of 
intracellular glutathione levels. These results have been published recently in ACS Nano 
(2008, 2, 2213-2218).   
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Figure 5.1: (a) Schematic illustration of the monolayer protected gold nanoparticles used 
as transfection vectors in this study. (b) Chemical structures of headgroups presented on 
the surface of the nanoparticles. 
 
5.2 Results and Discussion 
Fabrication of vectors: Amino acid-conjugated thiols were synthesized in a 
straightforward procedure with terminal ammonium group(s). 1-Pentanethiol-protected 
gold clusters (Au-C5, core diameter ≈ 2 nm) were functionalized with these ligands via 
the Murray place-exchange reaction providing water-soluble particles.33 To explore the 
structural effect of headgroup structure on tranfection efficiency, we fabricated three 
vectors (NP-LysG1, NP-Lys, and NP-Gly) featuring varying density of cationic sites 
(Figure 5.2).   
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Figure 5.2: General scheme for synthesis of amino acid-coated nanoparticles. 
 
Nanoparticle-DNA complexation: The comparable sizes of DNA and small 
functionalized nanoparticles facilitate their interaction.34 In our previous studies, we have 
demonstrated that quaternary ammonium-functionalized gold colloids effectively 
recognize DNA strands.35 Nanoparticles bearing primary ammonium groups (pKa ≈ 10) 
on the surface are also expected to bind with anionic DNA via ion-pairing at 
physiological pH (pH = 7.4).36  Gel electrophoresis was carried out initially to test the 
association of nanoparticles with DNA (gWiz β-gal plasmid). Nanoparticle-DNA 
mixtures at molar ratios (MR = molNP:molDNA, at a fixed amount of DNA) of 200 
(MR200) and 2000 (MR2000) were electrophoresed on agarose gel and stained with 
ethidium bromide (EtBr). While a band corresponding to free DNA was observed at 
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MR200 suggesting incomplete complexation, electrophoretic mobility of DNA toward the 
positive electrode was completely retarded at MR2000 (Figure 5.3). Binding was further 
verified by an EtBr exclusion assay, which indicated complexation between DNA and 
nanoparticles by quenching of EtBr-fluorescence (Figure 5.4).  
 
 
 
 
Figure 5.3: Gel retardation assay demonstrating DNA-nanoparticle complexation. A 
constant amount of DNA (333 ng/well) was complexed with nanoparticles at two 
different ratios in HEPES (10 mM, pH 7.4). No NP-DNA band is observed because of 
fluorescence quenching by NP complexation.   
 
  
 
 
Figure 5.4: Addition of cationic nanoparticles (NP-Lys) displaced intercalated ethidium 
bromide within DNA and resulted in a decrease in fluorescence. 
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Characterization of nanoplexes: Surface charge and size of DNA complexes are 
two important parameters in determining the efficiency of cellular uptake. Zeta potential 
measurements revealed that complexes of each headgroup (MR2000) bear positive surface 
potentials ranging from +25 mV to +34 mV (Table 5.1) that should promote initial 
adhesion on negatively charged cell surface.37 In general, polycation-DNA complexes 
enter into mammalian cells via endocytosis, a process that is limited to particles smaller 
than ~150 nm in diameter.38 Dynamic light scattering (DLS) showed that NP-Gly formed 
large complexes (> 150 nm). However, efficient condensation was achieved by 
increasing the density of ammonium groups on the particle surface. NP-LysG1 condensed 
DNA (<100 nm) most effectively (Table 5.1).  In addition to enhanced cellular uptake, 
the tight packing with NP-LysG1 should prove useful for cancer gene therapy, where 
particles ~100 nm can more easily extravasate through open endothelial gaps in tumor 
tissues.39,40   
Table 5.1: Surface charge and size of nanoparticle-DNA complexes (mol ratio 2000) in 
HEPES buffer (10 mM, pH 7.4) at 25 °C. 
 
 
nanoparticles zeta potential (mV) size (nm) 
NP-LysG1 30 ± 2 91 ±2 
NP-Lys 34 ± 1 112 ±1 
NP-Gly 25 ± 1 233 ±40 
NP-TMA 34 ± 2 118 ±10 
 
                                                
 
 
Transfection of mammalian cells: We have shown earlier that trimethyl 
ammonium-functionalized nanoparticles (NP-TMA) can protect DNA substantially from 
DNAse digestion,41 and transfect 293T cells in the presence of serum and chloroquine.20 
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An X-gal staining assay was conducted to qualitatively assess the amino acid-coated 
nanoparticles mediated transfection of monkey kidney cells (Cos-1) with a β-
galactosidase (β-gal) reporter plasmid at MR2000. After 3h of staining, blue spots were 
detected under an optical microscope from cells transfected with NP-LysG1 and NP-Lys, 
indicating that these particles serve as effective gene delivery agents (Figure 5.5).   
 
 
Figure 5.5: Optical micrographs showing transfected cells turned blue after 3h of X-gal 
staining. Cos-1 cells were transfected with β-gal reporter gene using (a) NP-LysG1 and 
(b) NP-Lys. 
 
The expression of the β-gal reporter gene was monitored by enzyme activity assay 
to quantify the efficiency of DNA delivery. First, Cos-1 cells were treated with 
nanoparticle-DNA complexes at various ratios (MR1000, MR2000, MR4000 and MR6000) to 
determine the optimal ratio for transfection. Expression of β-gal was maximal at MR2000 
(Figure 5.6), consistent with our previous studies.20 We next compared transfection 
efficiency of the synthesized nanoparticles at MR2000. As illustrated in Figure 5.7, lysine-
coated particles NP-Lys and LP-LysG1 efficiently expressed the reporter gene, whereas 
NP-Gly showed negligible enzyme activity. Cells were also transfected with two other 
effective vectors as positive controls, previously reported NP-TMA20 and extensively 
studied polylysine.42,43 Lysine and lysine dendrimer-coated particles were significantly 
better than both positive controls (Figure 5.7). In particular, NP-LysG1 and NP-Lys were 
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superior to polylysine by ~28 fold and ~5 fold, respectively. As expected, no measurable 
β-gal activity was detected when cells were treated with naked DNA.  
 
Figure 5.6: Transfection efficiency of NP-LysG1 at different mixing ratio. MR2000 was 
the optimal ratio. 
 
 
Figure 5.7: Enhanced transfection using NP-LysG1 and NP-Lys relative to positive 
controls, NP-TMA and polylysine (pLys). No appreciable enzyme activity was observed 
in the absence of vectors. Inset shows solution colors during a β-Gal activity assay 
performed after transfection. The color changes from yellow (substrate) to red (product) 
in the presence of active enzyme.  
 
Cytotoxicity: Cellular metabolic activity was measured by an alamar blue assay 
to evaluate possible toxicity that might arise from nanoparticles during transfection. As 
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depicted in Figure 5.8, amino-acid coated particles displayed no decrease in viability. 
However, trimethyl ammonium functionalized particles were moderately toxic, which 
probably originates from their strong interaction with the cell surface.44  
 
Figure 5.8: Cell viability determined by an alamar blue assay at the end of transfection 
(total period 48 h) using the optimum molar ratio (MR2000).  
 
Glutathione regulation of transfection efficiency: The cationic ligands of Au 
nanoparticles can be displaced by glutathione (GSH), which would alter the surface 
charge and loosen the DNA-NP association (Figure 5.9a).45,46 This mode of release 
utilizes the dramatic differential between extra- and intracellular GSH levels. Moreover, 
manipulation of intracellular GSH levels provides a potential mechanism for external 
control of transfection. We investigated the regulation of transfection efficiency of 
nanoparticles, NP-Lys (MR2000), by both increasing and decreasing intracellular GSH 
concentration. The glutathione level was transiently increased by treating cells with 
glutathione monoester (GSH-OEt).26 Glutathione monoester is rapidly internalized by 
cells and processed into glutathione (GSH) by esterases.47 Transfection efficiency 
increased upon treatment of cells with GSH-OEt in a concentration-dependent fashion 
(Figure 5.9b). In a complementary study, baseline GSH production was suppressed by 
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prolonged (24 h) treatment of cells with L-buthionine-[S,R]-sulfoximine (BSO), an 
inhibitor of γ−glutamylcysteine synthetase.48 As expected, BSO-treated cells showed 
lower transfection efficiency compared to untreated cells (Figure 5.9c).  
 
Figure 5.9: (a) Schematic depiction of place-exchange between native cationic ligands 
and cellular glutathione (GSH) on nanoparticle surface. (b) Elevation in transfection level 
depending on dose of glutathione monoester (GSH-OEt). Cells were pre-incubated with 
GSH-OEt for 1 h then washed prior to transfection. (c) Decrease in transfection 
efficiency upon L-buthionine-[S,R]-sulfoximine (BSO) treatment. Cells were plated in 
BSO-added (2 mM) media and incubated for 24 h.  
 
 
5.3 Conclusion 
In summary, we have demonstrated that coating gold nanoparticles with lysine-
based headgroups produces effective transfection vectors. DNA delivery efficiency 
strongly depends on the structure of headgroups and their concomitant ability to condense 
DNA. The lysine dendron-functionalized nanoparticle NP-LysG1 was most effective at 
condensing DNA, and was the most potent vector, ~28 times more effective than 
polylysine. Importantly, these amino acid-functionalized particles showed no cytotoxicity 
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when used as transfection agents. These materials were also responsive to cellular 
glutathione level during in vitro transfection, providing insight into their mode of activity 
as well as being a potential tool for orthogonal control of transfection.  
 
5.4 Experimental Section 
Materials. All chemicals were purchased from Aldrich unless otherwise stated. 
The organic solvents were bought from Pharmco-Aaper and used as received except 
dichloromethane and toluene which were distilled in the presence of calcium hydride. 
Flash column chromatography was carried out for purification using silica gel (SiO2, 
particle size 40-63 µm). gWiz β-gal plasmid (8278 bp) was purchased from Aldevron 
(Fargo, ND). L-Glutathione reduced ethyl ester (GSH-OEt) was obtained from Fluka. 
Cell culture medium powder and phosphate buffer saline (PBS) were bought from 
Aldrich. 
Gel electrophoresis: To prepare each mixture (27 µl total volume), 400 ng DNA 
was incubated with required amount of nanoparticles at room temperature in 10 mM 
HEPES buffer (pH = 7.4). After 10 min of incubation, 3 µl gel loading dye (6x) was 
added into each mixture. 25 µl from the resulting 30 µl solution was loaded into 0.6% 
agarose gel, pre-stained with EtBr. The samples were electrophoresed at 100 V for 60 
min in TBE buffer (0.045 M Tris-borate; 0.001 M EDTA) and the bands were visualized 
on a UV trans-illuminator.  
Ethidium bromide (EtBr) exclusion assay: The dye exclusion assay was tested 
with NP-Lys. A mixture of pDNA (1.2 nM), EtdBr (5 µM) and NP-Lys (0 µM, 0.24 µM 
and 2.4 µM) were incubated for 10 min in phosphate buffered saline (PBS, Sigma). Then 
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fluorescence (λem = 595 nm, λex = 545 nm) was monitored on a SpectroMax M5 micro-
plate reader (Molecular Device). Nanoparticle absorbance was corrected using NP-TEG, 
a neutral particle. Addition of particles resulted in release of intercalated dyes and hence 
decreases fluorescence intensity. 
Cell culture: Cos-1 cells were cultured in a humidified atmosphere (5% CO2) at 
37 °C. The cells were grown in Dulbecco's Modified Eagle's Medium (DMEM, 4.0 g/L 
glucose) supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin 
and 100 µg/ml streptomycin). All transfection experiments were performed with 
complete growth medium without antibiotics and in the presence of 100 µM chloroquine.  
1×105 cells per well were seeded on a 24-well plate 24 h prior the experiments. For GSH-
OEt treatment, old medium was removed after 24 h of plating, and cells were incubated 
with fresh medium containing GSH-OEt for 1 h and washed three times with PBS before 
adding transfection medium.26  
Transfection protocol:  All experiments were done in triplicate. Nanoplexes 
were first prepared at room temperature as follows (for 3 wells): (a) a 100 µl solution of 
2.4 µg plasmid and a 200 µl solution of the required concentration of nanoparticles were 
prepared separately in PBS, (b) after 5 min, particles were mixed with DNA and 
incubated together for 10 min. The nanoplexes were diluted with 1600 µl pre-warmed 
DMEM with 100 µM chloroquine. The resulting transfection medium was added into 
wells (600 µl/well, 3 wells) after washing cells once with PBS. 6 h later, the medium was 
removed, cells were washed 3X with PBS, and complete medium (600 µl/well) was 
added for another 42 h of incubation. Cells were transfected similarly with 
  79
polylysine/DNA at a mass ratio of 2.5 as previously reported (Mw of pLys ≈ 50K).42 Gene 
expression and cytotoxicity were tested after 48 h of total transfection period.  
X-Gal assay: Cells were stained following the assay kit (Genlantis, USA). After 
3h of staining, cells were washed twice with PBS and visualized on an optical 
microscope (Zeiss, 20x).  
Reporter gene expression: β-Gal activity was assayed using chlorophenol red-β-
D-galactopyranoside as a substrate (CPRG kit, Genlantis, USA). Absorbance (A570) was 
measured on a SpectroMax M5 micro-plate reader (Molecular Device), and the amount 
of expressed protein was calculated from a calibration curve constructed with pure β-gal. 
Total cellular protein was determined by bicinchoninic acid assay (Pierce, USA) 
according to the manufacturer’s protocol. 
Cytotoxicity assay: The alamar blue assay was performed according to the 
manufacturer’s protocol (Invitrogen Biosource, USA). After 48 h of transfection, cells 
were treated with 10% alamar blue solution and kept at 37°C for another 2 h. Red 
fluorescence, resulting from the reduction of alamar blue, was monitored 
(excitation/emission: 535/590) on a SpectroMax M5 micro-plate reader (Molecular 
Device).  
DLS and zeta potential: DLS experiments and zeta potential measurements were 
carried out using a Malvern Zetasizer (Nano series, Malvern Instruments Inc, USA). 
Nanoplexes were prepared as mentioned above in transfection protocol using HEPES (10 
mM, pH = 7.4) only instead of PBS/media. After 10 min of incubation, data were 
collected and reported as an average of three measurements.  
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Synthesis of NP-Gly and NP-Lys: NP-Gly and NP-Lys were prepared according 
to literature procedures.49,50  
Synthesis of Trit-C11-LysG1-(Boc)4: A dichloromethane solution of LysG1-
(Boc)4-OH51 (2.50 g, 3.11 mmol), Trit-C11-OH (1.00 g, 2.24 mmol), N, N'-
dicyclohexylcarbodiimide (DCC, 0.69 g, 3.34 mmol), and 4-dimethylaminopyridine 
(DMAP, 0.08 g, 0.65 mmol) was stirred at room temperature for 12 h. The solution was 
poured into a mixture of dichloromethane and distilled water. The organic layer was 
collected and purified by column chromatography on silica gel using n-hexane/ethyl 
acetate
 
(1:2, v/v) as an eluent, to give Trit-C11-LysG1-(Boc)4 as a white solid (Yield 2.40 
g, 87 %). 1H NMR (400 MHz, CDCl3) δ 7.41 (m, 6H, Ph-), 7.27 (m, 6H, Ph-), 7.20 (m, 
3H, Ph-), 7.00 (brs, 1H) 5.93 (brs, 1H), 5.60 (brs, 1H), 4.92 (brs, 1H), 4.76 (brs, 1H), 
4.35 (brs, 2H), 4.11 (brm, 3H, -CH2-O- and COCH(R)NH-), 3.10 (brs, 6H, -CH2NHBoc), 
2.12 (t, J = 7.3 Hz, 2H, -S-CH2-), 1.40 (m, 72H, -CH2- and CH3-); MS (ESI-MS) calcd 
for C68H106N6O12S 1231.7, found 1254.0 [M+Na]+. 
Synthesis of HS-C11-LysG1: A dichloromethane solution of Trit-C11-LysG1-
(Boc)4 (0.2 g, 0.16 mmol), trifluoroacetic acid (TFA, 0.6 ml), and triisopropylsilane 
(TIPS, 0.03 ml) was stirred at room temperature for 6 h under argon. After removal of the 
solvent at reduced pressure, the residue was purified by washing with diethyl ether (20 ml 
x 5). After drying residue under high vacuum, white solid of product was obtained (Yield 
0.09 g, 94 %). 1H NMR (400 MHz, CD3OD) major peaks assigned δ 4.41 (brs, 1H), 4.13 
(brs, 2H, -CH2-O-), 4.00 (brs, 1H), 3.86 (brs, 1H), 3.50 (brs, 1H), 3.23 (brs, 2H), 2.95 
(brs, 6H, -CH2NHBoc), 2.51 (q, J=7.2 Hz, 2H, HS-CH2-), 1.40 (m, 36H, -CH2- and CH3-
); MS (ESI-MS) calcd for C21H47N7O3S 588.89, found 589.6 [M+H]+  
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Synthesis of NP-LysG1: 1-Pentanethiol-protected gold colloids were dissolved in 
dichloromethane (DCM) and ligands were dissolved in DCM-methanol (10:1, v/v) 
mixture. These solutions were separately purged with argon.  After 30 min of purging, 
they were mixed together and stirred at room temperature for ~ 48 h. Then solvents were 
evaporated and excess ligands were removed by 5X washing with DCM-methanol (50:1, 
v/v) followed by dialysis (cut off 10 kDa, Pierce) for 2 days.  
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 CHAPTER 6 
NANOPARTICLE-MEDIATED DELIVERY OF A MEMBRANE-
IMPERMEABLE ENZYME WITH RETENTION OF ITS ACTIVITY 
 
6.1 Introduction 
Delivery of functional proteins inside living cells provides a powerful tool for 
therapeutics and fundamental study of cell biology.1,2,3 This technique allows introduction 
of proteins in a rapid, time-specific and dose-dependent fashion.4 While significant 
progress in DNA-recombinant technology has lead to availablity of any protein of 
interest, protein transduction has been limited by the poor membrane permeability of 
most proteins, and hence requires a transporter.5 In one strategy, cell-penetrating peptides 
(CPPs) have been attached to proteins genetically or chemically to promote their 
translocation across plasma membrane.6 Nevertheless, covalent modification can generate 
challenges such as alteration of activity or the possibility of the tag being buried 
internally, and therefore a non-covalent approach has attracted tremendous attention.7,8 
Recently, supramolecular approaches using nanomaterials including silica nanoparticles, 
carbon nanotubes, and quantum dots have emerged as an alternative delivery 
strategy.9,10,11 However, efficient delivery with retention of bioactivity still remains a 
major challenge.  
Gold colloids are promising candidates in nanomedicine due to their bio-
inertness, non-toxicity and cellular imaging ability.12,13,14,15,16,17 They have been reported 
for DNA delivery, however, their use as protein carriers is largely unexplored18,19,20 due 
to challenges in protein recognition and structure retention.21 The large surface area and 
tunable functionality of gold nanoparticles makes them an excellent scaffold for protein 
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surface recognition.22,23 Moreover, the conformation of proteins can be preserved by 
tailoring the monolayer of particles.24 Herein, we have demonstrated the effective 
intracellular delivery of β-galactosidase (β-gal), a membrane-impermeable protein with 
high molecular weight (465 kDa) in a variety of cell lines, with endosomal escape and 
retention of activity inside the cells (Figure 6.1).  
 
 
Figure 6.1: (a) Schematic representation of intracellular delivery of functional protein 
using gold nanoparticles. (b) Structure of the nanoparticle, the protein cargo, and the 
ligand onto particle. 
 
6.2 Results and Discussion 
We fabricated peptide-coated gold nanoparticles (NP_Pep, core diameter ~2.5 
nm) to serve as a protein transporter. Three functional domains were incorporated into 
particle structure: the interior alkyl chains impart stability to the core, a corona of 
tetraethylene glycol (TEG) prevents both non-specific interaction with biomolecules and 
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denaturation,24 the exterior peptide-tags serve as a recognition unit. Polyarginine is well-
known for translocating molecules across the plasma membrane.25,26,27,28,29 Therefore, our 
initial attempt was to functionalize the particles with a short peptide containing three 
arginine residues (NP-RRR), however, it rendered particles not dispersible in water. On 
the other hand, we have earlier experienced lysine-coated particles as water-soluble and 
stable for at least a year.30 As a result, we chose a reported sequence comprising of both 
arginine and lysine,31 with an additional histidine residues which is known to facilitate 
endosomal escape of the cargo.32,33 Overall, the peptide headroup consisting of strong and 
weak basic amino acid residues (Arg, Lys and His) serves multiple roles: (a) protein 
surface recognition and plasma membrane association through favorable electrostatic 
interaction and hydrogen bonding of the guanidino moiety, and (b) “endosomal 
buffering” due to the presence of the proton-sponge imidazole group of histidine.34,35,36 
Importantly, these particles (NP_Pep) were nicely dispersed in aqueous media with 
similar to anticipated hydrodynamic diameter of 12.9 ± 0.3 nm.37 They were cationic in 
nature with zeta potential of 32 ± 1 mV. 
Nanoparticle-β-gal complexation was assessed by fluorescent titration using 
fluorescein isothiocyanate-labeled β-galactosidase (FITC-β-gal). As expected, FITC-
fluorescence was quenched by the gold core upon addition of NP_Pep allowing us to 
quantify the interaction of the cationic particles and anionic β-gal (pI 4.638), with a KD of 
1.0 nM observed (Figure 6.2). Surprisingly, we found that this complexation was stable 
enough for not dissociating in 150 mM salt solution within 2 h (long enough period for 
endocytosis39), presumably due to additional hydrogen-bonding interactions of the protein 
with the arginines of the nanoparticle.40,41 Analysis of circular dichroism (CD) spectra 
  88
revealed that there was minimal change in secondary structure in presence of 
nanoparticles (Figure 6.2). Similarly, no shift in λmax of tryptophan-fluorescence of the 
protein was observed (Figure 6.3), further confirming retention of the native structure of 
the protein.42  
 
Figure 6.2: (a) Fluorescence titration of FITC-β-gal with NP_Pep in 5 mM phosphate 
buffer at 25 °C. (b) The percent of secondary structures calculated using DICHROWEB 
indicating minimal conformational change upon nanoparticle addition. 
 
 
Figure 6.3: No shift in λmax of tryptophan-fluorescence upon addition of nanoparticle. 
Cellular delivery of β-gal protein was first monitored using FITC-β−gal as a 
fluorescent probe. Human cervical carcinoma cells (HeLa) were treated with 2:1 molar 
ratio NP_Pep/FITC-β-gal complexes, as precipitation occurred at higher particle/protein 
ratios in media. Following 3 h of incubation, cells were washed and cultured for another 
3 h. Green fluorescence was observed when cells were treated with particle-protein 
complexes, while cells incubated with FITC-β-gal alone displayed no fluorescence 
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(Figure 6.4a-b). Cells treated with the complexes also showed presence of gold from 
inductively coupled plasma mass spectrometry (ICP-MS), consistent with the expected 
nanoparticle-promoted co-translocation of this membrane-impermeable protein (Figure 
6.4c). The delivery process could also take place in presence of serum as evident from 
microscope images (Figure 6.5). 
 
Figure 6.4: Fluorescence micrographs of Hela cells transfected with FITC-β-gal (50 nM) 
(a) in absence or (b) in presence of NP_Pep (100 nM). (c) ICP-MS measurements after 
treating cells with NP_Pep/β-gal (100 nM/50 nM) complex at different temperatures, and 
cells treated with β-gal alone as a control. (d-f) CLSM images of HeLa cells after protein 
transfection (NP_Pep/FITC-β-gal: 100 nM/50 nM): (d) bright field, (e) fluorescence and 
(f) their merge.  
 
 
 
Figure 6.5: Images captured by fluorescence microscopy after protein transfection in 
presence of serum (a) without and (b) with nanoparticles. Cell were treated with 
NP_Pep/FITC-β-gal (100 nM/50 nM) complex in DMEM media with 10% serum for 3 
h, then washed with PBS and cultured for another 3 h before taking the images. 
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Figure 6.6: CLSM images of HeLa cells treated with NP_Pep/FITC-β-gal (100 nM/50 
nM) at 4 °C and 37 °C. Protein signal was less at 4 °C, and located mainly near the 
surface as indicate by arrows.  
 
We next performed confocal laser scanning microscope (CLSM) experiments to 
confirm that the observed fluorescence was coming from inside the cells as opposed to 
adsorbed on the cell surface. As shown in micrographs, punctate fluorescence was 
present in the perinuclear region of the cells, indicating protein internalization, 
presumably via endocytosis (Figure 6.4d-f).43 This mechanism was supported by 
substantial decrease in fluorescence (Figure 6.6) coupled with a decrease in gold (via 
ICP, Figure 6.4c) with uptake experiments performed at 4 °C.44   
Current research has been focused on cytoplasmic delivery of proteins. As the 
complex entered into cells via the endocytic pathway, we investigated whether the cargo 
was able to escape from the endosome or not. For this purpose, cells were treated with 
FM 4-64, a red color endosome-specific marker.45 FITC-fluorescence that arises from 
delivered FITC-β−Gal was monitored along with red-fluorescence from FM 4-64 using 
CLSM (Figure 6.7a-b). After merging the green and the red channels, we observed 
presence of significant amount of green dots within the cells with some yellow dots, 
indicating most of the proteins were outside the endosomes (Figure 6.7c). The proteins 
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entrapped inside the vesicles appeared as yellow dots that originated from overlapping of 
green and red spots.  
 
Figure 6.7: A colocalization study using CLSM after protein transfection 
(NP_Pep/FITC-β-gal: 100 nM/50 nM) of HeLa cells in presence of FM 4-64: (a) green 
fluorescence from FITC-β-gal, (b) red fluorescence from FM 4-64, an endosome-specific 
marker, and (c) overlap of the green and the red channels. In the merged image, green 
spots (shown with green arrowheads) are indicating proteins outside endosomes, while 
entrapped proteins inside endosomes appear as yellow dots (shown with yellow 
arrowheads). 
 
Enzymatic activity provides a particularly stringent test for the retention of 
bioactivity after transduction, a key concern in protein delivery. The NP_Pep/protein 
complex was incubated with HeLa cells for 6 h followed by treatment with X-gal, a 
colorless substrate for β-gal that turns blue upon enzymatic hydrolysis. Significantly, 
blue precipitates appeared inside cells transfected with the particle-protein complex, 
demonstrating preservation of enzymatic activity after delivery (Figure 6.8b). No color 
was observed, as expected, when cells were treated with protein alone (Figure 6.8a). As 
shown earlier in the CLSM images, X-gal staining of the cells after trypsin digestion also 
suggested that the proteins were internalized by the cells as opposed to adsorbed onto cell 
surface (Figure 6.9). With longer culture period (24 h) after transfection, we observed the 
expected decrease in the enzymatic activity (Figure 6.10).  
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Figure 6.8: (a-c) X-gal staining after transfection. (a) HeLa with protein only. 
Transfected (b) HeLa and (c) C2C12 cells with NP_Pep/β-gal (100 nM/50 nM). (d) The 
percent of transfection with NP_Pep/β-gal (100 nM/50 nM) in defferent cell lines. (e) 
Dose-dependent protein delivery into HeLa cells at 2:1 NP_Pep/β-gal. 
 
 
 
Figure 6.9: X-gal staining after trypsin digestion. After 3 h of β-gal (50 nM) transfection 
(a) without and (b) with NP_Pep (100 nM), cells were washed, trypsinized and then 
allowed 4 h more to reattach before X-gal staining. 
 
 
 
 
Figure 6.10: Decrease in the percent of transfection after a day as observed by X-gal 
staining. HeLa cells were treated with NP_Pep/FITC-β-gal (100 nM/50 nM) for 3 h, 
washed with PBS, and cultured for another 3 h and 24 h before X-gal staining.  
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We next studied the dose-dependent response of the delivery system, a useful tool 
for controlled protein delivery. Cells were treated with varied concentration of the 
enzyme, and protein delivery was assessed by X-gal histochemical staining. The 
percentage of transfected cells, judged by positively stained cells, increases with dose, 
with quantitative transfection (~98%) achieved at 100 nM of protein concentration 
(Figure 6.8e). Significantly, efficient transfection (>80%) was observed at 50 nM of 
protein in a diverse array of cell lines, including COS-1 (monkey kidney cells), MCF7 
(human breast cancer cells), and even hard-to-transfect muscle cells (C2C12) (Figure 
6.8c-d).46  
Concurrent with our delivery studies we investigated the cytotoxicity of the 
NP_Pep particles. From a trypan blue exclusion test, we observed no cell death after 3 h 
of transfection as well as even after a day of transfection (Figure 6.11). This lack of 
toxicity was also validated from calcein AM assay (Figure 6.12). Importantly, full 
retention of cell vitality was observed from alamar blue assay (Figure 6.11).  
 
 
Figure 6.11: Nanoparticles showed no toxicity even after 24 h of protein transfection as 
measured by (a) trypan blue exclusion test and (b) alamar blue assay. 
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Figure 6.12: Green fluorescence from cells after calcein AM assay indicating they are 
alive. 
 
6.3 Conclusion 
In summary, we have reported a highly efficient strategy for intracellular protein 
delivery. Supramolecular complexes with engineered nanoparticles were shown to 
translocate exogeneous proteins into a variety of cells without exhibiting any 
cytotoxicity. Crucially, the transported enzyme was able to escape from endosmes and 
retained its biological activity, providing the potential for fundamental and therapeutic 
applications of this strategy. We are currently investigating delivery of therapeutic 
proteins.  
 
6.4 Experimental Section 
Materials. All chemicals were bought from Aldrich unless otherwise stated. The 
organic solvents were purchased from EMD and used as received except 
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dichloromethane and toluene which were distilled in presence of calcium hydride. For 
purification, flash column chromatography was performed using silica gel (SiO2, particle 
size 40-63 µm). Amino acids and resin were purchased from Advanced ChemTech 
(USA). β-Gal, cell culture medium powder and phosphate buffer saline (PBS) were 
purchased from Sigma. FM 4-64 was purchased from Molecular Probes (Invitrogen, 
USA).  
Synthesis of peptide-conjugated ligand. The peptide was synthesized manually, 
using standard Fmoc chemistry with Rink resin (0.7 mg/g) as a solid support.  Side-chain 
protecting groups were as follows: trityl-chloride (Trt) for histidine; 2,2,5,7,8-
pentamethylchroman-6-sulfonyl (Pmc) for arginine; tert-butoxycarbonyl (Boc) for lysine. 
Fmoc deprotection was carried out  using 20% piperidine in DMF for 15 min, and amino 
acid (5 eq) coupling was performed  using HBTU (5 eq), HOBt (5 eq) and DIPEA (10 eq) 
in DMF for 1 h (Figure 6.13). 
The trityl-protected thiol linker (5 eq) was conjugated to the peptide using 1,3-
diisopropylcarbodiimide (DIC, 6 eq) and HOBt (7.5 eq) in a overnight reaction. The thiol 
linked peptide was cleaved/deprotected for 1.5 h using Reagent B: 88% trifluoroacetic 
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Figure 6.13: The procedures for peptide-ligand synthesis (* indicates protected side 
chains). 
 
acid (TFA), 5% phenol, 5% water and 2% triisopropylsilane (TIPS). TFA was 
then removed under vacuum, and the ligand was precipitated with cold diethylether. The 
crude product was purified by reverse phase high pressure liquid chromatography (RP-
HPLC) and then analyzed by mass spectrometry (calculated 986.6, obtained 987.6; 
M+H+) (Figure 6.14).  
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Figure 6.14: The MALDI-TOF mass spectra of the synthesized peptide ligand. 
Synthesis of functionalized gold nanoparticle. 1-Pentanethiol-coated gold 
nanoparticles (10 mg) were dissolved in dichloromethane (DCM), and peptide ligands 
(20 mg) were taken in methanol. After purging argon into them separately for 30 min, 
they were mixed together and stirred for ~2 days at room temperature (Figure 6.15). Then 
solvents were rotavaped, and excess ligands were washed away with DCM-methanol 
(20:1, v/v; 5X)) followed by dialysis (cut off 10 kDa, Pierce) for 2 days. Absence of free 
ligand was verified by NMR, and particles were characterized by UV, DLS and TEM 
(Figure 6.16).  
 
Figure 6.15: Functionalization of nanopaticles via Murray place-exchange reaction. 
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Figure 6.16: UV spectra and TEM image of the peptide functionalized gold 
nanoparticles. 
 
Labeling of β-gal with FITC. Fluorescein isothiocyanate isomoer I (FITC) was 
dissolved in dimethyl sulfoxide at a concentration of 4 mg/mL. The β-gal (2.5mg) was 
dissolved in 900 µL of 0.1 M sodium bicarbonate solution (pH 9.0), and mixed with 250 
µL freshly prepared FITC solution. The mixture was protected from light and stirred at 
room temperature for 2 h. The resulting FITC labeled β-gal was purified by size 
exclusion chromatography with Sephadex G-25 as stationary phase and phosphate buffer 
(5mM, pH 7.4) as mobile phase. Finally, the β-gal concentration and labeling efficiency 
(β-gal:FITC=1:16) were measured by ultraviolet-visible absorption spectroscopy.  
β-Gal-nanoparticle binding experiment. FITC-β-gal (100 nM) was mixed with 
NP_Pep at various molar ratios in 5 mM phosphate buffer (pH 7.4) for 10 min at room 
temperature. The fluorescence was recorded on a Spectro-Max M5 microplate reader 
(Molecular Device) (Ex 490 nm and Em 520 nm). Absorbance due to nanoparticles was 
corrected with control TEG-OH nanoparticle.47 The corrected intensities were plotted and 
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fitted with a nonlinear equation (eqn 1) using Origin 8, providing KD value (0.97 ± 0.58 
nM) and binding ratio (NP_Pep:β-gal = ~ 8:1).42 The effect of salt on the complex 
(NP_Pep:β-gal = 8:1) was monitored for 2 h. 
 
 
Where Ks = association constant, n = binding ratio (considering identical binding 
site)  
Circular Dichroism. CD spectra of β-gal (100 nM) were taken with or without 
nanoparticles (200 nM) in 5 mM phosphate buffer after 10 min of complexation. It was 
performed on a Jasco 720 spectrophotometer using a quartz cuvette of 1-mm path length. 
After equilibration at 25 ºC for 5 min, the spectra were acquired by scanning from 250 
nm to 190 nm. Average of three scans was recorded at a rate of 20 nm/min with 8 sec 
response and 0.1 nm interval. The final spectra were obtained by subtracting the blank 
one and it was fitted into secondary structure algorithm CDSSTR (protein ref. set 7 
comprising of 49 proteins, http://www.cryst.bbk.ac.uk/cdweb/html/home.html) using 
DICHROWEB.  
Tryptophan fluorescence measurement. Fluorescence spectra were measured in 
a 1 cm quartz cuvette on a Photon Technology International fluorescence spectrometer at 
25 °C. Tryptophan fluorescence was monitored at 310~450 nm wavelength by exciting at 
295 nm. Spectra of 100 nM of β-gal solution were collected without/with NP_Pep (200 
nM) in 5 mM phosphate buffer (pH 7.4) at 25 °C.  
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Cell culture. HeLa cells were cultured in a humidified atmosphere (5% CO2) at 
37 °C, and grown in Dulbecco’s modified eagle’s medium (DMEM, low glucose) 
supplemented with 10% fetal bovine serum (FBS, Aldrich). C2C12 and COS-1 cells were 
cultured in high glucose media (DMEM, high glucose) with 10% FBS. MCF7 cells were 
cultured in low glucose media (DMEM, low glucose) with 10% FBS. 
β-Gal delivery. Cells (HeLa: 3x104 per well, C2C12: 6×104 per well, COS-1: 
6x104 per well) were seeded on 24 well plate. Next day the β-gal-nanoparticle mixture 
was added onto cells after washing with phosphate buffer saline (PBS). β-Gal was mixed 
with NP_Pep in 5 mM phosphate buffer (pH 7.4) for 10 min, and then diluted 6X with 
DMEM without serum. The cells were incubated with the transfection medium (protein-
nanoparticle complex in DMEM without serum) for 3 h, and then washed with PBS (3X) 
followed by another 3h of culture in DMEM with 10 % FBS. 
Fluorescence and confocal microscopy. Cells were washed twice with PBS 
before capturing images. Fluorescence pictures were taken on an Olympus IX51 inverted 
microscope keeping all parameters the same for different samples. Confocal pictures 
were obtained on a Zeiss LSM 510 Meta microscope using a 40X objective.  
ICP- MS measurements. ICP-MS measurements were performed on a Perkin-
Elmer Elan 6100.  The operating conditions were as follows:  RF power: 1250 W; plasma 
Ar flow rate: 15 L/min; nebulizer Ar flow rate: 0.96 L/min; dwell time: 50 ms; nebulizer: 
cross-flow; spray camber: Scott. 
After enzyme (NP_Pep/β-gal: 100 nM/50 nM) delivery, cells were washed twice 
with PBS and then lysis buffer (250 µL/well, 30 min; Genlantis, USA) was added. Cell 
lysate was digested overnight with 3 mL nitric acid and 1 ml of hydrogen peroxide.  The 
  101
following morning, 1 ml of freshly prepared aqua regia (caution!) was added and allowed 
to react with the sample for one more hour.  The sample was heated to 100 °C to reduce 
volume of the above digestion to ~1 mL.  It was then diluted to 10 mL using a volumetric 
flask with ultra pure water and additional aqua regia (5% final concentration).  Each 
sample was measured in quadruplet via ICP-MS as described above.  A series of gold 
standards containing 5% aqua regia was prepared and ran prior to the samples (20, 10, 5, 
2, 1, 0.5, 0.2, 0 ppb).  The gold uptake in each sample was determined from the resulting 
calibration line.  Deionized water was used to wash the instrument between each sample 
analysis. 
X-gal assay. Cells were stained according to the assay kit (Genlantis, USA). After 
12 h of staining, cells were washed once with PBS and observed under an optical 
microscope (Nikon/Spot-RT). Experiments were performed in duplicate. For counting, 
four pictures (each having ~30 cells) were taken randomly from each replica and then 
averaged.  
Cytotoxicity assays. A trypan blue exclusion test was performed to count live 
cells. After transfction with mentioned concentration of β-gal at molar ratio of 2, cells 
were cultured for some period (3 h or 24 h) and then they were trypsinized. Then cells 
were centrifuged, redispersed in PBS, mixed with 1:1 trypan blue (Fluka) and counted 
(duplicate, more than 100 cells for each replicate) on hemocytometer.   
Live/dead cells were also assayed using calcein AM (Viability/Cytotoxicity Kit, 
Invitroge, USA) after transfection with NP_Pep/  β-gal (200 nM/100 nM) according to 
the manufacturer’s protocol. 
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The alamar blue assay was carried out following the manufacturer’s protocol 
(Invitrogen Biosource, 102SA). After delivery, cells were treated with 10% alamar blue 
solution and kept at 37 °C for another 2 h. Red fluorescence, resulting from the reduction 
of alamar blue, was monitored (Ex: 560 nm, Em: 590 nm) on a SpectroMax M5 
microplate reader (Molecular Device).  
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CHAPTER 7 
CONCLUSION AND FUTURE DIRECTIONS 
 
The enormous power of synthetic chemistry could enable to tailor the surface 
coating of nanoparticles in any way we desire. As described in the previous chapters, this 
surface coating plays a pivotal role for communicating with biological systems. With 
proper design of ligand structure, we were able to use functionalized gold nanoparticles 
for controlling their interactions with biomolecules and delivery of therapeutics. Needless 
to say, more in depth investigations are required to achieve a feasible nanocarrier of 
therapeutics. In this chapter, some important factors to be considered have been outlined 
and on-going research is focusing on those aspects.  
 
7.1 Cellular Uptake of Nanoparticles  
Cellular uptake of nanoparticles is likely to be most influenced by surface 
functionality, as it is initiated through recognition at the plasma membrane. While small 
molecules (molecular weight < 500 Da) can easily diffuse through membrane, intake of 
nano-sized materials occurs through specific and/or non-specific interaction(s) with the 
cell surface.1 Non-specific adsorption will depend on the nature of the surface charge and 
its density. Normally cationic nanoparticles strongly interact with cell surface through 
favorable electrostatic interaction, while anionic/neutral/zwitterionic particles are 
expected to be less readily internalized.2  
Low uptake of zwitterionic particles can reduce the possible cytotoxicity. 
Considering this factor and the fact that these particles have strong resistance to serum 
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protein adsorption, we chose them as a carrier of small molecular drugs. Hydrophobic 
drugs/dyes were loaded into the “hydrophobic pocket” of NPs with high stability. We 
have also demonstrated release of caged molecules into cancer cells by membrane-
mediated diffusion without uptake of the carrier nanoparticle (Figure 7.1). This study has 
been published recently in Journal of the American Chemical Society (2009, 131, 1360). 
Importantly, the small size of these nanocarriers coupled with their biocompatible surface 
functionality should provide long circulation lifetimes and preferential accumulation in 
tumor tissues by the enhanced permeability and retention (EPR) effect. Additionally, the 
non-interacting nature of their monolayer should make these systems highly amenable to 
targeting strategies. 
 
Figure 7.1: Entrapment of hydrophobic molecules into the NP monolayer and delivery of 
payload to cell through monolayer-membrane interactions. 
 
7.2 Looking into the Uptake Mechanism 
Surface functionalization could dictate the uptake pathway and the localization of 
nanoparticles into cellular compartments.  A class of peptides, termed as cell penetrating 
peptides (CPPs), has been developed to promote efficient crossing of cell membrane 
barrier.3 The CPPs are able to transport attached nanoparticles from the extracellular 
space through the cell membrane into the cytoplasm. In a recent study, Stellacci et al. 
have demonstrated that distribution of hydrophobic ligands on particle surface could 
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regulate cellular uptake of nanoparticles – ‘striped’ nanoparticles slipped through 
membrane, but ‘unstructured’ particles were less readily internalized.4  
Targeting to specific organelles is of great importance in order to enhance the 
therapeutic efficacy. However, cytosolic delivery of payloads from nanocarriers is limited 
mainly by their endosomal entrapment. Nie et al. reported cell-penetrating quantum dots 
(QDs) with endosomal disrupting surface coatings.5 The authors showed that the 
polyethylene glycol (PEG) grafted and hyperbranched polyethylenimine (PEI) coated 
QDs were able to escape from acidic intracellular organelles to cytoplasm. To this end, 
we are also investigating the uptake mechanism of only nanoparticles or their complexes 
with biomolecules. As shown in the TEM image (Figure 7.2), a large amount of gold 
nanoparticles (NP_Me) were trapped inside vesicles in the cytoplasm (most likely via 
endosomal entrapment). In some cases, we have used additives like chloroquine to assist 
in endosome disruption.  
 
 
Figure 7.2: Transmission electron microscopy (TEM) image of fixed cell (HeLa) treated 
with NP_Me.  
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7.3 Toxicity of Nanoparticles  
Concurrent with uptake studies, toxicity of the nanoparticles should be assessed 
carefully for their use as drug delivery agents. As the particles are intentionally designed 
to interact with cells, there is always a concern about possible adverse effects.6 In vitro 
cytotoxicity assays, such as the alamar blue assay (metabolic activity), calcein AM and 
ethidium homodimer assay (live/dead), and trypan blue exclusion test (membrane 
integrity) are only the starting point. They should be carried out in different cell lines 
with various incubation times. Hemolysis is another issue in the design of drug delivery 
agents.7,8 It is important to balance delivery efficiency with hemolytic activity 
(colorimetric assay using Drabkin’s reagent) to create useful delivery agents. 
Genotoxicity of these particles should be considered as well. In this regard, 
measurements are required for DNA damage, generation of reactive oxygen species 
(ROS), or any change in gene expression. 
To provide insight into the origins of toxicity of funtionalized gold nanoparticles, 
we used MTT, hemolysis, and bacterial viability assays to explore differential toxicity 
among cell types, using 2 nm core particles featuring cationic and anionic functionality.9 
These studies show that cationic particles are moderately toxic, with relatively little 
discrimination between erythrocytes, Cos-1 cells, and E. coli. In contrast, anionic 
particles are quite non-toxic, with no effect observed on cell viability at any of the 
concentrations studied. The probable mechanism for toxicity was established as lysis 
through dye release studies using lipid vesicles. As discussed earlier, cationic headgroups 
facilitate cell membrane penetration. Therefore, we are studying cytotoxicity and 
genotoxicity of cationic particles by varying the alkyl tail length (Figure 7.3). The results 
  109
indicated that the cell viability decreased by the particles with longer alkyl chains 
(NP_Me>NP_Et>NP_Bu>NP_Hex). However, NP_Me caused extensive DNA damage 
as observed in a comet assay.  
 
Figure 7.3: A study on toxicity of cationic particles: (b) alamar blue assay for measuring 
metabolic activity and (c) comet assay of cells treated with NP_Me. 
   
7.4 in vivo Targeting 
For in vivo applications, the goal of nanocarriers is to arrive at the diseased tissues 
after administration into circulatory system. Two approaches have been developed for 
targeting – namely ‘passive’ and ‘active’ targeting (Figure 7.4).10,11 ‘Passive’ targeting 
depends on homing of the vectors in unhealthy tissues due to extravasation through leaky 
(gaps ~ 600 nm) blood vessels. An important aspect of carrier systems in the 5-10 nm 
scale is their ability to take advantage of the enhanced permeation and retention (EPR) 
effect (Figure 7.4).12 On the other hand, ‘active’ targeting presents ligands on the carrier 
surface for specific recognition by cell surface receptors. The ligands could be small 
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molecules, peptides or proteins. Combination of both types of targeting will render an 
ideal carrier for in vivo delivery.   
 
Figure 7.4: A schematic illustration of drug delivery via ‘active’ (solid line) and 
‘passive’ (dotted line) targeting. 
 
Nanocarriers suffer from non-specific uptake and potential degradation in 
macrophages. Therefore, targeting is crucial for maximizing drug efficacy while 
minimizing side effects. Pun et al. have studied how different physicochemical 
properties, such as size, PEGylation, or the ligand, regulate nonspecific versus target-
specific uptake of nanoparticles.13 They concluded that (a) PEGylation increased blood 
circulation life-time (comparing unmodified-NP and PEG-NP), (b) Galactose, a ligand, 
facilitated filtration of Gal-PEG-NPs into liver (comparing PEG-NP and Gal-PEG-NP), 
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and (c) the ligand rendered cell-specific targeting of hepatocytes. Folic acid (FA) and 
methotrexate (MTX) have been exploited by several groups as targeting molecules.14 
They are specifically recognized by folate receptors that are overexpressed on the 
surfaces of many tumor cells.  
We have considered these known targeting molecules, like folic acid and 
galactose, for conjugation with our delivery systems. At the same time, using multiplexed 
screening ability of our newly developed tool as described in chapter 4, we are looking 
into finding new targeting molecules. In a preliminary study, we have already seen some 
degree of differentiation in uptake of the cationic particles between two cell lines (Cos-1 
and SVR-Bag 4) we tried.  
 
7.5 Outlook 
Nanomaterials are now not only confined inside the four walls of a research 
laboratory, they have started to reach into market slowly. According to a 2008 report, 
more than 186 nanotech-based drugs and delivery systems have entered into preclinical 
or clinical trials worldwide.15 Gold nanoparticles have emerged as a promising scaffold 
for delivery of therapeutics that provides a useful complement to more traditional 
delivery vehicles. The combination of low inherent toxicity, high surface area, and 
tunable stability provides them with unique attributes that should enable new delivery 
vectors. Full realization of their potential, however, requires addressing a number of open 
issues, such as acute and long-term health and environmental effects of nanomaterials, as 
well as scalable, reproducible manufacturing methods for these materials. 
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